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Abstract
One of the key goals of modern medicine is to treat patients individually, recognizing
the heterogeneity that exists within them and thus hoping to provide them with more
effective personalized therapies. ‘-Omics’ patient data provides a valuable resource to
understand the patient heterogeneity and gain an insight into the biological phenom-
ena at the intracellular level. As it is impossible to dissect patient groups based on sin-
gle biomarkers or clinical factors, multivariate data mining and statistical modelling ap-
proaches (machine learning) play an important role. Moreover, understanding complex
disease mechanisms calls for a more comprehensive and integrative approach, hence mo-
tivating the use of different kinds of data from the same patient. As individual -omics
data sources capture specific kinds of molecular phenomena, there is a pressing need for
multi-modal statistical approaches which combine several kinds of -omics data together.
The present thesis addresses the aforementioned issues, viz. the exploration of het-
erogeneous patient populations based on their multi -omics profiles using statistical and
machine learning approaches. More specifically, the main contributions of the thesis
include: a) a retrospectively validated prediction model for GBM (Glioblastoma Mul-
tiforme) recurrence location and b) development of a new algorithm- Survival based
Bayesian Clustering which is a merger of clustering and supervised prediction, this al-
gorithm has been successfully shown to be an important step towards the discovery of
clinically relevant patient strata leveraging the potential of multi-omics data integration.
The novel algorithm of Survival based Bayesian Clustering was tested successfully in
various scenarios and on different patient populations. The thesis also provides a deep
understanding of our proposed technique from a purely statistical point of view. Over-
all, work in this thesis is a step forward in moving towards the goal of personalized
medicine solutions using multi-modal molecular -omics data and statistical modelling.
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“The fundament upon which all our knowledge and
learning rests ॾ the inexplicable.”
Arthur Schopenhauer
1
Introduction
1.1 Patient Stratification in Cancer
Modern medicine aims at providing a much more personalized treatment of an individual
which is tailored to his/her personal characteristics. This approach is fundamentally dif-
ferent from traditional medical practice which is based on the idea of reference treatments.
These reference treatments are ’canonical’ treatments which have been established based on
13
large series of patients and are considered universal solutions for treating new patientsGW08 .
Diseases such as cancers are known to be highly heterogeneous and may designate, in fact, a
myriad of different diseases, each with its own trajectory.
It has been shown that cancer can be characterized by complicated accumulation of ge-
netic and epigenetic alterations thus leading to a lot of heterogeneity within itselfBCH+12.
The idea of patient stratification in this context is to acknowledge that the patient pathol-
ogy is unique and this uniqueness is driving the choice of treatment. Such a personalized
treatment (and hence strata of patients) depends on patient’s constitutional genetic back-
ground as well as tumor’s genetic and epigenetic landscape.
One can easily realize the importance of acknowledging the diversity within patient pop-
ulation in cancer. This diversity and hence stratification is important to:
• Design separate clinical/medical treatment protocols for different strata of patient
population
• Better understand the complicated set of molecular alterations within the sub-populations
and hence develop stratum- specific drugs.
The second point leads us to defining Biomarkers and its application in PersonalizedMedicine.
1.2 PersonalizedMedicine & Biomarker Discovery
Patient stratification is the first step towards individualized treatment also know as Person-
alized, precision, P4, or stratified medicine. A concrete definition of PersonalizedMedicine
was adopted by EUHealth Ministers in their Council as follows: “a medical model using
characterization of individuals’ phenotypes and genotypes (e.g. molecular profiling, medi-
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cal imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at
the right time, and/or to determine the predisposition to disease and/or to deliver timely
and targeted prevention”.*
Personalized medicine can be understood as an approach in which patients are strati-
fied based on their predicted disease subtype, disease risk, disease prognosis or treatment
response using diagnostic testsBFM18. It is a rapidly advancing field of health care which is in-
formed by each person’s unique genetic, clinical and genomic information. A key promise
of personalized medicine is a much closer molecular understanding of disease to optimize
preventive/diagnostic/prognostic health care strategies and drug therapies. As the afore-
mentioned factors are different for every person hence the nature of disease, its onset, its
course, and how it might respond to drug or other interventions are as individual as the
people who suffer from themFBB+18. Briefly, personalized medicine allows the following
practical advantages †:
1. Better and informed clinical decision making and disease management
2. Better-targeted therapies that will result in higher desirable outcomes
3. Reduced ill-effects from targeted-therapies.
4. Earlier disease detection and possible disease prevention
5. Reduced health care costs.
*The document can be accessed at: http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:
C:2015:421:FULL&from=EN
†EU commission report on ’The use of ’-omics’ technologiॽ in the development of personalized medicine’
can be accessed at: https://ec.europa.eu/research/health/pdf/2013-10_personalised_medicine_en.
pdf
15
6. Smarter design of clinical trials due to selection of likely responders at baseline
Personalized or precision medicine stratifies patients into groups based on many factors
which include the biological make-up or biomarkers. A formal definition of a biomarker
was provided by the National Institutes of Health Biomarkers Definitions Working Group
as “a characteristic that is objectively measured and evaluated as an indicator of normal
biological processes, pathogenic processes or pharmacological responses to a therapeu-
tic intervention.”Gro01. The US Food and Drug Administration (FDA) defines the term
biomarker as any measurable quantity or score that can be used as a basis to stratify pa-
tients, e.g., genomic alterations, molecular markers, disease severity scores, lifestyle char-
acteristics etc.BFM18.
From a clinical application point of view biomarkers may potentially be used to pre-
dict clinical responses to treatments, and in some cases they may represent potential drug
targets. Biomarkers in clinical research can be obtained from solid tissues and bio-fluids.
Various kinds of biomarkers have been used in clinical practice to detect diseases and pre-
dict clinical outcomes. The FDA lists more than 160 pharmocogenomic biomarkers and
biomarker signatures which have been used for stratifying patients for drug responseMS17.
Personalized medicine and Biomarker identification are tightly interconnected. It is im-
portant to mention that in many cases, it’s difficult to identify single biomarkers which can
stratify patients. This is due to the complex nature of diseases (especially cancer) which of-
ten involves an interplay of many different biological subsystems. Also, drugs for treating
diseases are multi-faceted and hence single biomarkers fail to describe their effect. Multi-
variate biomarker signatures are therefore seen as promising solutions, a highly cited exam-
ple is MammaPrintVVDVDV+02 , a 70-gene signature for predicting breast cancer prognosis.
16
Discovery of such multi-dimensional signatures require advanced statistical models and
machine learning methods applied on -omics data sets (genomics, transcriptomics, epige-
nomics, proteomics, metabolomics). Recently, bio-imaging data (MRT and CT)MCM+06,
electronic medical records (EMRs) JJB12 have also been used for biomarker discovery.
1.3 MultiModal Data& StatisticalModelling
The ambitions of personalized medicine and biomarker discovery have been tremendously
boosted by the ever growing data availability and the generation of large volumes of high-
throughput ‘-omics’ data capturing large scale biology (genome, proteome, transcriptome).
A more comprehensive definition of -omics data is provided in the next chapter. We also
have (in many cases) large volumes of clinical longitudinal data for patients from Electronic
Medical Records (EMR). These various different kinds of data can be referred to as multi-
modal (omics, clinical) data as there are different modalities giving rise to these data. This
multi-modal data is critical to the goals of personalized medicine and biomarker discovery
as it contributes to a much finer understanding of disease at different levels, this in turn
might lead to the identification of new biomarkers which might be predictive of the de-
velopment of a disease, disease prognosis or medicine response or as targets for new treat-
ments. During the course of our present work we focus on the data sources originating
from different ‘-omics’ approaches, such as genomic variation and mRNA expression analy-
sis plus the clinical data such as time-to-event.
Statistical Models are tools to analyze this multi-modal data. As the data generated from
these multi-modal data is highly multi-dimensional it requires multivariate statistical mod-
els. Pre-processing and appropriate normalization methods first prepare the raw multi-
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modal data for further application of statistical learning models (also know as machine
learning models). The goal of these statistical learning/ machine learning models is to gain
insight into the complex structure present within the data and to provide accurate predic-
tions. This essentially involves separating the interesting signals from the noise present in
such data. Statistical models capture the statistical dependencies, such as correlation from
the data and allow for more comprehensive approaches in PersonalizedMedicine/Biomarker
discovery.
Multi-modal data is widely believed to provide unique opportunities for Personalized
Medicine as it allows for capturing and understanding different dimensions of a patient.
This aspect could in turn be key for enhancing prediction performance of patient stratifi-
cation statistical models to a level useful for clinical practice.BFM18. There is also the benefit
of a deeper understanding of disease mechanisms: recent progress in the investigation of
independent ‘omic’ resources has shown that there is a possibility that the molecular pro-
files or patterns observed in the potential biomarkers may not be true reflections of primary
molecular events which initiate or modulate a diseaseBCH+12. This occurs because disease
development is a highly complicated consequence of interplay of different bimolecular
pathways. This complicated association of the different large scale biological processes with
one another calls for a more holistic and integrative approach. Such an approach not only
concentrates at one data source but integrates multi-source data (e.g. multi-omics data sets).
The integration of different modalities of clinical and multi-omics data also motivates the
present work. In this thesis we refer to multi-modal data in the context of multi-modal -
omics data, i.e. data representing different biological modalities and focus on integrating
this multi-modal omics data with clinical outcome. We show that such an integrated ap-
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proach leads to the development of advanced exploratory/predictive approaches for patient
stratification and biomarker discovery.
1.4 Glioblastoma: Case Study in Patient Stratification
Glioblastoma (GBM) is a grade IV astrocytoma, which is the most common primary adult
brain tumor. GBM is a fast-growing and most aggressive type of central nervous system
tumor Som17. The last decade has seen many influential high throughput microarray stud-
iesPKC+06,VHP+10b on GBM. This line of research has been quite successful to understand
GBMmore comprehensively. Although the median survival remains low despite advances
on many aspects, due to this work there is an increasing understanding of many aspects of
this extremely complex disease. In that context, The Cancer Genome AtlasMFB+08 has been
tremendously beneficial for identifying GBMmolecular subtypes along with several gene
signatures that have been proposed for risk stratification in GBM patients.
One of the key characteristic features of Glioblastoma is that this tumor varies widely in
its composition with both inter and intra tumor heterogeneity. Prior to the advent of tech-
nologies to decipher the molecular makeup of glioblastoma, histopathology was the only
modality available to characterize the tumor and its variants. TheWorld Health Organi-
zation in its 2016 classification, characterizes glioblastoma in two major groups prognostic
groups based on mutational status of IDH (Isocitrate dehydrogenase) gene-IDHwild type
glioblastoma and IDHmutant glioblastoma. It is believed that IDHmutant glioblastoma
confers a significantly better prognosis than IDHwild type glioblastoma Som17. Other key
molecular biomarkers for this disease include: Losses of Chromosomal Arms 1p and 19q,
ATRXmutations, TP53 mutations, TERTmutations, EGFR amplifications, PTEN and
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MGMTmutations. It has also been established for nearly a decade that Epigenetic silencing
of MGMT gene through its promoter methylation results in better response to Temozolo-
mide and it was the most advocated prognostic marker in glioblastoma Som17. Glioblastoma
was also among the first cancers to be targeted by large scale molecular profiling platforms
like comparative genomic hybridization (CGH), single nucleotide polymorphism (SNP)
arrays among other omics data types.
In 2006, Phillips et al.PKC+06 classified Glioblastoma into three subgroups- Proneural,
Proliferative andMesenchymal with the Proneural group showing best prognosis. They
used Olig2, DLL3, BCAN(Proneural), PCNA, TOP2A(proliferative), YKL-40, CD44 and
VEGF (mesenchymal) as biomarkers to identify their subtypes. In a later work in 2008,
Parson et al.PJZ+08 brought the vital molecule IDH1 (Isocitrate dehydrogenase 1)to the fore-
front. In later years, Verhaak et al.VHP+10b radically altered the molecular classification and
identified four subgroups namely: Proneural, Neural, Classical andMesenchymal. They
focused on alterations in PDGFRA, IDH1, EGFR, and NF1 and further highlighted the
importance of IDH1 mutation which was seen in the Proneural group predominantly.
Though both these groups of scientists (Phillips et al. and Verhaak et al) used distinct
methodologies and sample sets, the proneural and mesenchymal groups were robustly con-
cordant in their molecular profilingDRR+13.
Apart from large heterogeneity, Gioblastoma is also notorious for its inevitable recur-
rence after maximal safe resection in spite of concomitant radiation and chemotherapy
following surgery. The recurrent tumor tends to come back in a more aggressive man-
ner which is more resistant to therapy. Presently, there is no accepted standard therapy
for recurrent glioblastoma. Also, there have not been many studies focusing on recurrent
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glioblastoma. One major reason for this is that not all recurrent tumors are operable, hence
limiting the access to the recurrent tumor tissue. Therefore the scarcity of paired tumor
samples precludes any molecular studies on recurrent glioblastoma. Most recurrences are
predominantly local (recurring within 2 cmmargin of the original tumor) with only a small
proportion coming back as distant recurrences (recurring distantly in a different lobe or in
contra-lateral hemisphere)GRS+10. The genetic makeup of the local recurrences when com-
pared to their its primary counterpart still remains largely unknown.
1.5 IDENTIREST project
In this thesis we develop statistical models for our own -omics data from Glioblastoma
patients from the IDENTIREST (Identifizierung neuer Therapieansätze durch Analyse
Residualer Tumorzellen) project, funded by the German Federal Ministry of Research and
Technology (BMBF) from 2013 till 2016. The goal of the project was to find new candidate
drug targets and prognostic biomarker signature for glioblastoma. With our new statistical
method (Survival based Bayesian Clustering and its subsequent variations) we identify new
patient strata in this cohort with significantly different prognosis.
In this project, two kinds of samples are available for each GBM patient: a)the routinely
removed and conventionally studied GBM cells (known also as central samples) from the
centre of the tumor resection site and b) Residual cells (known also as peripheral sam-
ples) obtained from the periphery of the tumor resection site. The genetic landscape of
local recurrences (peripheral samples) was initially thought be similar to the original tumor
(central samples). The IDENTIREST project strives to clarify the status of these local re-
currence samples, thus gaining molecular insights into the samples from spatially adjacent
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areas(residual) of the primary tumor. The goal of the IDENTIREST project was the char-
acterization of these residual cells with the aim to identify new drug targets.
The project builds on the past work ofGRS+10 which concentrated on the isolation and
initial characterization of vital residual tumor cells of GBMs. We explore the heterogene-
ity of the central as well as the residual samples via our statistical models. A further unique
contribution of our work is a classification model which allows us to predict with high ac-
curacy the tumour recurrence, hence opening a perspective for preventive treatment of re-
currence in GBM patients.
1.6 Thesis Contributions
The aforementioned challenges are addressed in this present thesis. The core contribu-
tions of our work are two fold: a) development of classification model in the context of the
IDENTIREST project where we successfully predict the spatial recurrence of GBM, and
b) formulation of a novel statistical model which uses multi-modal omics data along with
clinical outcome data for patient stratification. The development of our statistical model
is motivated by the question of patient stratification in Gliobalstoma. From a technical
point of view, our Survival based Bayesian Clustering model (or SBC) can be considered as
a combination of supervised and unsupervised approaches. The SBC which takes in clinical
end-points of patients along with heterogeneous -omics data, performs two tasks in one -
a) patient sub-group identification on training data and b) prediction of patient sub-group
and survival time on testing data. It’s based on the motivation of discovering clusters of pa-
tients using their distinct molecular signatures and strong survival curve separabilityAF17.
The plausibility of our SBC approach also lies in the biological interpretability of our re-
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sults. The whole thesis is structured as follows:
• Chapter 2 introduces the broad field of -omics data sets and their use in personalized
medicine, it talks about the challenges of using single -omics data sets in patient strat-
ification, builds the motivation and application of integrated multi-omics in patient
stratification. The chapter also provides a qualitative overview of the various statisti-
cal and machine learning methods and approaches that have been devised for the use
of multi-omics data sets in patient stratification.
• Chapter 3 talks about some of the practical applications of machine learning meth-
ods to personalized medicine in glioblastoma treatment in the context of the IDEN-
TIREST project. It introduces the various facets of the project, including the differ-
ent omics data sets generated and the potential questions that were answered using
different machine learning methods. The last section of this chapter is about the vital
contribution in the development of classification model which predicts the spatial
recurrence of Glioblastoma in the IDENTIREST cohort of samples. This model is
further validated on an independent data set, thus promising to be of importance
from a clinical point of view.
• Chapter 4 is the most important part of the thesis from a methodological point of
view. It contains the novel statistical model (SBC) along with the motivation and
application of the same. Many different questions that can be answered using this
model are explored and results on two publicly available cancer data sets are pro-
vided. The results and biomarkers are also explored further for their biological rele-
vance. Overall, this chapter introduces a novel machine learning method in patient
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stratification and establishes the clinical and biological veracity of the results.
• Chapter 5 gives examples of the application of our SBC approach in Glioblastoma
patient stratification. Two different variations of SBC are used to tackle different
questions about the glioblastoma data set.
• Chapter 6 elucidates the statistical foundations of SBC and its relationship to other
similar methods. The chapter situates SBC as a broad machine learning algorithm
which can be seen from different points of views. It explains the similarities and dif-
ferences with other popular machine learning/statistical methods.
• Conclusion draws the whole thesis to an end summarizing the core message of pa-
tient stratification and the use of SBC for this purpose. It also talks about the sci-
entific accomplishment of the present thesis and its limitations along with future
directions for research in multi-omics data for personalized medicine.
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“Every answer given on principle of experience begets a
fresh question.”
Immanuel Kant
2
Machine Learning approaches to patient
stratification using multi-modal omics data
2.1 Introduction toOmics Data
As discussed in the last chapter, one of the goals of patient stratification is providing per-
sonalized treatment. This involves identifying new translational targets in nucleic acid char-
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acterizations. In cancer, we know that a series of events occurring at the cellular level dis-
rupt the normal behavior of the cellBCH+12. Currently, it is believed that cancers always orig-
inate from genomic or epigenomic aberrations. However, consequences of these aberra-
tions can manifest at different biological levels, namely transcriptome, proteome, metabolome
etc. Moreover, the interactome between the proteins is probably also affected. Addition-
ally, these changes affect how other kinds of molecules interact with each other, e.g., inter-
actions between transcription factor and DNA.We need biotechnology tools which allow
us to better understand tumour progression and improve the classification of tumours.
Thus, there is a need to comprehensively quantify the aforementioned changes which occur
at different molecular levels. Current -omics biotechnologies enable us to accurately char-
acterize these molecular profiles of each tumor sample: Genomics investigates the DNA
alterations (mutation, copy number), miRNomics the microRNA (miRNA) expression,
transcriptomics the mRNA expression, proteomics the different proteins, epigenomics the
epigenetic modifications like methylation and so onBCH+12 . A full graphical description of
all the different omics technologies can be seen in Fig.2.1.
In the past two decades the advent of omics data sets including genomics, transcrip-
tomics, methylomics and proteomics, has created a huge source of cellular information
on the one hand and stimulated parallel developments in statistical methodology and in-
ference, computational tools on the other. Within the context of genomic medicine in can-
cer research, we focus our attention to different -omics data sources used for personalized
medicine along the integration of this high-throughput data frommultiple platforms to
inform our understanding of the functional consequences of genomic alterations. We now
briefly touch upon the technologies used for measuring omics data sets.
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The first successful attempt at sequencing DNAwas made by SNC77 and facilitated the
full sequencing of both genes and entire genomes. In spite of the fact the method was
resource-intensive Sanger sequencing remained the standard method for the coming two
decades. The method since its inception has gone through many refinements and technical
advancements which increased its efficiency and reliability during the next three decades.
Still, Sanger sequencing required large investments. A breakthrough came just before the
turn of the century with the emergence of microarrays in the market that lessened run time
and could be operated more easily with fewer human resources. Hence, microarray plates
started replacing the labor-intensive Sanger method in the mid-1990s. The microarray tech-
nology rapidly became the default method to assess the expression of virtually all genes.
The microarray technology, since its inception has been adapted in many different forms:
Figure 2.1: Illustrated diagram for different omics data sets. Image reproduced fromBCH
+12 under free copy license
CC-BY-SA.
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genome microarrays like array Comparative Genomic Hybridisation (aCGH) or Single
Nucleotide Polymorphism (SNP) arrays which investigate genomic alterations like gain,
deletion and point mutations (for SNP arrays); transcriptome arrays for quantifying RNA
expression at the the exon level or the transcript level, or microRNA (miRNA) expression;
proteome arrays which interrogate protein expression and activities; Chromatin Immuno-
precipitation (ChIP) arrays for localizing on the genome protein-DNA interactions or in-
vestigating nucleosome modifications SSD+95.
The microarray technology provides measurements with the ability to quantify the
genome-wide expression of thousands of gene on a tiny slide. Generally, for applications
in personalized medicine, concentration of the mRNA or SNP array are measured across
a range of samples originating from diseased and healthy patients. This provides concen-
tration of a particular gene’s transcript at a discrete point in time and differences in expres-
sion of the same gene across many samples could provide information to disease specific
biomarkers.
Since the mid 2000s, Next-generation sequencing (NGS) has been becoming increas-
ingly popular, NGS allows for simultaneous sequencing of millions of DNA fragments
without previous sequence knowledge. NGS is also capable of looking through the entire
genome or transcriptome. Since their inception NGS technologies are becoming more and
more economically and technically viable, thus increasing in their popularity and often re-
placing microarrays as high throughput omics data sources for DNA (DNA-Seq), RNA
(RNA-Seq) and proteins (ChIP-seq). However, in the context of this thesis only omics data
measured via microarray technologies was used (largely due to cost considerations).
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2.2 Omics Data in PersonalizedMedicine
The above mentioned omics biotechnology (producing high-throughput data) has pro-
moted our understanding of the molecular nature of tumors, thus helping us unravel the
genetic variations at different molecular levels. Many diseases, like cancer are known to be
caused by genetic mutations and hence omics data provide a rich source of evidence to iden-
tify these mutations along with the possible mechanisms underlying such mutations. Hu-
man cancers are primarily genetic diseases and they can often be characterized by the follow-
ing molecular changes: DNA sequence changes, copy number aberrations, chromosomal
rearrangements and epigenetic modifications such as DNAmethylationBCH+12. These up-
stream effects on the DNA can be captured using DNAmicroarray or DNAmethylation
arrays. Later or downstreammodifications can be understood using mRNA or miRNA
and reverse-phase protein microarrays. The overall disease is a complex combination of the
aforementioned malignant and trans-formative changes.MFB+08. The high-throughput tech-
nologies allow for screening of massive amounts of omics-type data. In order to discover
clinically relevant molecular markers (also known as biomarkers) one needs to associate
such data with a patient’s clinical prognosis or with the membership to a clinically relevant
disease subtype (positive drug response class vs negative drug response class)CF12a.
Traditionally, within each disease (like cancer) patients are usually stratified into sub-
categories based on clinical information gathered from the patient, such as his/her age and
possible previous cases of cancers in his/her family, and about the tumor, such as its size,
location or histological type under the microscope. Generally, these informations are col-
lectively referred to as clinicopathological parameters. Such stratification of patients is of
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great value in clinical management. Also, for most cancers, guidelines exist to suggest the
best therapeutic choices based on these stratification. For example, in Breast Cancer in
addition to the histological parameters, the presence of specific markers, such as estrogen
(ER), progesterone (PR) and human epidermal growth factor (HER2) receptors, is eval-
uated by immunohistochemical methods. Aggregated, these clinicopathological parame-
ters currently determine the choice of the therapy proposed to the patient. In spite of the
enormous help of such stratification technique for patient management, this approach is
limited. Firstly, the consistent and objective assessment of some clinicopathological factors
is difficult to make sure. This means that it might not only vary with the particular histo-
logical section being studied, but also might depend on the expert analyzing the sample.
Secondly, this coarse classification fails to identify many differences between patients that
are important for therapeutic treatment and monitoring. It has been known that tumors
with similar clinicopathological parameters frequently follow different clinical courses or
respond differently to therapies, hinting at the fact that a further level of variability exists
within clinicopathological subtypes. Thirdly, clinicopathological parameters do not take
into account the molecular differences, which likely have a tremendous impact on disease
prognosis and optimal therapy. These limitations of traditional patient stratification calls
for a more in-depth and finer classification.
The development of the several aforementioned high-throughput omics technologies
has started to revolutionize the way we approach the problem of patient stratification, espe-
cially in cancer. Moreover, several omics technologies such as DNAmicroarrays ensure an
unbiased and systematic collection of data, potentially facilitating novel discoveries in hith-
erto unexplored domains. Gene expression profiling was historically the first omics tech-
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nique that was available and has been the most widely employed omics technology used in
the area of personalized medicine. The systematic profiling of various cancer types has been
among the first applications of microarray-based transcriptomic studies in the early 2000s
(e.gAED+00,BKH+02, SPT+01),the gene expression microarray providing measurements of a set
of patients allowing measurement of the biological phenomena and for discovering pat-
terns that potentially allow insights into disease mechanisms. Moreover, microarrays have
also been used to identify diagnostic, prognostic and therapeutic biomarkers which are clin-
ically relevant. Many questions related to cancer diversity have potentially been addressed
when molecular omics data are collected on different tissues and patients. For example:
• Is there observable diversity at the molecular level corresponding to that which we
are already familiar with at the macroscopic level or under the microscope?
• Is it possible to define new, robust classification schemes based on molecular biomark-
ers ?
• What biological insight (mechanisms, pathways of action) can we get from compar-
ing the molecular portraits of diverse samples?
• Is it possible to obtain better disease prognosis models and better predictive biomark-
ers for therapy response?
One of the hypothesis that researchers have tried to ascertain is the fact whether some of
the clinicopathological parameters such as the dosage of protein markers are directly related
to measures that we can perform at the molecular level, such as the expression level of the
corresponding or related genes. It has indeed been shown by the likes ofDHKW+08 that the
ER and HER2 status usually measured by pathologists in the clinics can be recovered, with
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good accuracy, from the expression level of a few genes (see Fig.2.2). This allows in principle
the automatic classification into the classical subtypes based on the expression profiles (see
Fig.2.3). A landmark work in the area of using omics data set for Breast Cancer stratification
identified a 70-gene signatures for metastasis prognosisVVDVDV+02,VDVHV+02. This 70-gene
signature has been validated prospectively and led to an FDA approved diagnostic test for
clinical practice, MammaPrint®.
Spurred by the early success of using -omics data sets for clinically relevant patient strat-
ification, National Institute of Health launched The Cancer Genome Atlas (TCGA) -
omics data base back in 2006MFB+08. This project has generated comprehensive, multi-
dimensional maps of the important molecular changes in 33 types of cancer. The TCGA
dataset has also been made publicly available.Some years later, another massive world-wide
collaboration project, the International Cancer Genome Consortium (ICGC)HAA+10, was
Figure 2.2: Breast cancer diversity in 2 dimensions. Global view of the 286 tumors in the Wang dataset, organized in
terms of ER and HER2 status. Image reproduced fromBCH
+12 under free copy license CC-BY-SA.
32
Figure 2.3: Molecular subtypes in Breast Cancer from mRNA expression profiles. The heatmap is based on 286 sam-
ples in the Wang breast cancer dataset. Image reproduced fromBCH
+12 under free copy license CC-BY-SA.
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started with the goal of characterizing the molecular profiles of more than 50 cancer types
with larger tumor samples. The samples in both these massive databases are accompanied
with relevant clinical features along with corresponding molecular profiles which contain
genomic, transcriptomic and epigenomics profiles. Both these repositories are open source
and have resulted in large volumes of progress in patient stratification.
2.3 StatisticalMethods for single Omics Data
We now turn our attention to the statistical techniques used for multi-variate analysis for
single -omics data sets. Broadly speaking, there are two different paradigms of the statisti-
cal learning models when applied to patient stratification and biomarker discovery using
-omics data: the first approach is an exploratory one which is also known as ‘unsupervised’
learning. The goal of this approach is to discover meaningful patterns within the patient
population without being guided by any pre-defined patient classes (and thus the name un-
supervised). One is interested in different clusters of patient population which are closer
to one another than with those patients which are outside their cluster. This approach is
particularly interesting when we have no prior knowledge about the underlying patient (or
sample) population structure. Learning unsupervised models implies the learning of the
cluster-specific parameters. Unsupervised learning approaches model a set of inputs, based
on similarity without any reference to the class labels of those inputs. The model learning
phase discovers the class labels. Popular unsupervised learning approaches are: Hierarchi-
cal clustering Joh67, partition based methods like k-means and k-medoidsRK90 and matrix
factorization methods like NMF (Non-negative matrix factorization)LS99. Unsupervised
approaches for patient stratification strive on detecting subgroups frommolecular charac-
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terization of tumors with a hope of paving way for new, robust and unbiased taxonomies
of cancers. The goal of such unsupervised, exploratory analysis is to provide parallel strati-
fication schemes or to refine the classical stratification schemes based on clinicopathological
factors. It could also reveal new molecular factors underlying the stratification, such as the
activation of particular signaling pathways or the alterations of particular genomic regions,
thus consolidating our current understanding of the molecular underpinnings of cancers.
The second approach is known as supervised learning’ as it uses pre-defined patient
stratas (e.g. high risk vs low risk) to obtain its model parameters. This use of already defined
patient strata makes such models powerful from a predictive point of view. This means
that once the parameters of such a supervised model are learnt using a set of patient data
(known as training data), the model can then predict patient stratum for every new sample
(known as testing data). This predictive approach of supervised learning becomes espe-
cially relevant when we have prior knowledge about the patient strata and we would like
to stratify future patients based on our current data and model. Supervised learning gener-
ates a function that maps inputs to desired outputs (patient stratum also called class labels
which are pre-defined by human experts). This learnt function is then used to predict class
labels for other patients. Supervised learning uses patients clinical end-points (metastasis or
not, time to relapse, overall survival or disease evolution etc.) This, then can be combined
to define prognostic biomarkers which can be measured for future patients. These future
patients (patients not used for building the statistical model) can then then be classified
for example into high or low risk. This helps the physician to prescribe appropriate treat-
ment. The rationale for this decision making is as follows: most cancer patients after their
initial diagnosis and treatment are given adjuvant therapy in the form of cytotoxic drugs
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which have strong deleterious side effects. However, based on patient stratification, this
adjuvant therapy can be only given to high risk groups and thus sparing the low risk group
of the harmful side effects of Chemotherapy. Therefore such predicted stratification can
not only spare the morbidity of a treatment but can also justify a more aggressive adjuvant
treatment to patients belonging to the bad prognosis or high risk class. Class-labels could
be discrete (classification problem) or could be continuous indicators (like survival time).
Famous examples of supervised models applied in Patient stratification are: support vec-
tor machines (SVM)CV95, linear discriminant analysis (LDA)Wel05, multinomial regression,
Random forestsBre01, Cox regression, BoostingFSA99 etc.
Apart from stratifying patients into clinically relevant groups, statistical methods also
focus on identifying relevant biomarkers and signatures. Discovery of biomarker signa-
tures is an important aspect of the above mentioned statistical models. Owing to the of-
tentimes high dimensionality of the generated data, statistical methods (machine learning
algorithms) employ some kind of variable selection. Variable selection is employed due to
the fact that high-dimensional data contains a large amount of noisy, useless information
that needs to be filtered out. Hence, almost every statistical modelling technique used in
this domain also identifies few relevant features which could be of valueBVDG11. These few
relevant features can be interpreted as biomarker signatures. Variable selection not only al-
lows for the detection of a small set of features which can be later validated, it also allows
us to bypass important statistical challenges in high-dimensional statistics, viz. overfitting.
Overfitting refers to the phenomenon in which the statistical model describes the training
data perfectly, however performs poorly on unseen test data. When the number of samples
(which is typically of the order of some tens or hundreds) is much smaller that the number
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of features (of the order of some thousands), as is the case in most microarray technologies,
building robust and stable statistical models calls for efficient feature selection. In order to
tackle the problem of high-dimensionality, many advances have been made in the field of
high dimensional statistics which caters to the statistical modelling for high-throughput
omics data sets (seeCF12b for a comprehensive review) . High-dimensional statistics refers
to statistical inference when the number of unknown parameters p is of much larger order
than sample size n, that is: p  n. A successful signature is a relatively small collection
of q features, i.e. q  pwhich can validated on other external data sets. The problem of
defining a signature within the context of statistical modelling is associated with the more
general problem of feature selection in machine learning. Feature Selection is an integral
aspect of high-dimensional statistics, both in supervised and unsupervised approaches. It al-
lows to circumvent many problems including like high-dimensionality and high-correlation
within the omics data.
2.4 Motivation forMulti Omics Data Integration
The strength of data-driven statistical methods normally increases when more data are an-
alyzed jointly. Therefore, during the last years there has been an increasing interest to an-
alyze multiple, heterogeneous omics data in an integrated manner in order to gain a more
comprehensive picture on complex biological systemsHHR11. For example, large scale initia-
tives such as The Cancer Genome Atlas (TCGA) and the International Cancer Genome
Consortium (ICGC)HAA+10 now provide transcriptomics, methylomics, proteomics and ge-
nomics data of hundreds of patients for several cancer entities, allowing novel insights into
cancer biologyMFB+08. In the following section we review a few computational strategies
37
which have been proposed for integrative analysis over multi-modal omics data sets and the
associated challenges. The text that follows is closely adapted from our review paperAF16.
While most authors agree on the chances of omics data integration, the associated chal-
lenges have changed considerably over the last decades: While in the middle of the last
decade data availability was seen as one of the big issues, later works mention statistical
challenges, such as the risk of overfittingCP12, and the difficulties associated with different
technical platforms, for example differing normalization protocols and batch effectsKLR+14.
Altogether the challenges for integrating heterogeneous omics data may be summarized
as follows: omics data of different modality (e.g. transcriptomics vs. proteomics) are mea-
sured with different techniques. Hence, these data have differing numerical types (e.g. dis-
crete counts vs. continuous signals) and scales, coupled with large differences in the num-
ber of measured features (several hundreds of thousands of SNPs vs. few hundreds of miR-
NAs). Furthermore, each technical platform has another noise level and sensitivity. Con-
sequently, naive merging of heterogeneous omics data increases the dimensionality of the
data and thus increases the chance to produce false positive hypothesis testing results. In
a machine learning setting the chance increases to overfit the data. In order to circumvent
these problems the key question is therefore, how to identify and combine relevant features
from each data modality in a way that respects known biological dependencies.
The goal of the subsequent sections is to give an overview about recent statistical infer-
ence and learning techniques that have been devised to address issues related to multi-omics
data integration for patient stratification. HereAF16, instead of emphasizing specific math-
ematical details of selected methods, we try to characterize the overall methods landscape.
More specifically, we pose the question : in which way integrated omics data could be used
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for personalized patient treatment in a supervised as well as unsupervised learning setting.
We also focus on ideas adopted in the past to overcome the above mentioned challenges
vis-a-vis multi -omics data integration.
2.5 StatisticalMethods forMulti-Omics Data Integration.
As it has been mentioned before, one of the primary goals of personalized medicine is to
stratify patients into clinically relevant sub-populations based on suitable biomarker signa-
turesCF13. In this section we ask, in which way integrated omics data could be used for better
personalized patient treatment in a supervised as well as unsupervised learning setting. Dif-
ferent classes of algorithms are discussed for both application tasks. Existing and future
challenges for data integration methods are pointed out. An overview about the associated
statistical learning techniques discussed in this section can be found in Table 2.1 and 2.2.
2.5.1 Clinical Outcome Prediction
During the last decade computational research in the personalized medicine area has mainly
focused on learning predictive models based on one data modality (e.g. gene expression),
possibly also in combination with biological background knowledge (seeCF12b for a review).
The advent of multiple, heterogeneous omics data modalities from the same patient (e.g.
somatic mutations plus gene expression data) now raises the question, whether predictive
models which utilize several combined data sources could improve prediction performance.
Hence, the primary objective for omics data integration in personalized medicine is to en-
hance model learning and prediction performance.
In the machine learning community traditionally three general strategies for data inte-
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gration are distinguishedPWCG01,MGKP08: Early integration methods focus on extraction of
common features from several data modalities, resulting into one integrated data matrix. In
a second step conventional machine learning methods can then be applied. Late integration
algorithms first learn separate models for each data modality and then combine predictions
made by these models, for example with the help of a meta-model trained on the outputs
of data source specific sub-models. The latter strategy is called stackingWol92. Intermedi-
ate integration algorithms are the youngest branch of data fusion approaches. The idea
is to join data sources while building the predictive model. An example of this strategy is
Support Vector Machine (SVM) learning with linear combinations of multiple kernel func-
tionsLCB+04.
All three data integration strategies have been applied in the area of personalized medicine:
Pittman et al.PHD+04 integrated clinical and gene expression data into a Bayesian decision
tree classifier to predict breast cancer prognosis. Following an early integration approach
the authors first summarized gene expression data into meta-genesHIP+03, which were then
joined with clinical variables. Selection of relevant variables was carried out via forward se-
lection.
Boulesteix et al. first used partial least squares (PLS) regression to extract features from
gene expression dataBPD08. These features were then combined with clinical variables to
train a Random Forest classifier for predicting breast and colorectal cancer outcome. In a
similar vein Cao et al.LCMM10 proposed a mixture of experts model to jointly model the ef-
fect of gene expression and patient clinical data to predict patient outcomes, they concluded
that using gene expression data can provide valuable insights to understanding survival
mechanisms by identifying prognostic biomarkers.
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Gevaert et al.GST+06 employed a Bayesian Network to combine clinical and gene expres-
sion based on the 70 gene breast cancer signature by van’t Veer et al.vDv+02. The authors
compared an early integration strategy based on simple pasting of data matrices with an in-
termediate and a late strategy. In the intermediate integration the authors first learned sep-
arate BN structures for each data sources and then join these networks based on the node
representing the clinical outcome they had in common. In the late strategy only predictions
by the two separate BNmodels were weighted and aggregated. The authors found the in-
termediate strategy to be most promising.
Daemen and co-workers suggested the use of a multiple kernel learning (MKL) frame-
work to predict disease outcome of rectal cancer based on gene and protein expression data,
and of prostate cancer based on transcriptome and CNV dataDGO+09. Within the MKL
framework separate kernel functions were defined for each omics data modality. A linear
combination of these kernels was then employed to train a least squares SVM (LS-SVM).
The authors reported a better prediction performance of this intermediate data integration
strategy compared to model stacking.
Following again the idea of MKL, Thomas et al. suggested a weighted LS-SVM classi-
fier to combine gene expression and clinical dataTBSM14. Compared to models built on each
individual data modality as well as compared to an early integration strategy using gener-
alized singular value decomposition, the authors found a significant improvement of their
approach for predicting breast cancer outcome.
Wang et al.WBM+13 developed an integration scheme based on probabilistic graphical
models and Bayesian inference. Their iBAG algorithm (integrated Bayesian Analysis) com-
bines miRNA, DNAmethylation and mRNA data to predict patient survival of Glioblas-
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tomaMultiforme (GBM) patients. Their approach explicitly takes into account the bio-
logical relationship between different data modalities. The authors identified separate gene
sets related to disease outcome and demonstrated better prediction power to detect disease
related genes than non-integrative methods.
Gade et al. first constructed a correlation weighted bipartite miRNA-target gene graphGPF+11.
This graph was then used to guide feature selection with a component-wise likelihood
boosting algorithm for predicting prostate cancer outcomeBS09. Going one step further
other authors also considered protein-protein interaction informationCF13. Their method
first smoothes marginal t-statistics of genes and miRNAs over the structure of the inte-
grated PPI and miRNA-target gene network via random walk kernels. Most relevant fea-
tures are then determined via a permutation test. Subsequently a conventional SVM classi-
fier is trained. The authors demonstrated the benefit of this approach compared to stacking
for predicting disease prognosis in several cancers.
Arguable one of the most advanced but also computationally costly approaches for in-
termediate data integration in the field of personalized medicine has recently been sug-
gested by Zitnik and ZupanZZ14. The authors combined gene expression and histological
data from animals and human with protein-protein interactions and GO annotation to
predict liver injury induced by chemicals. This was done based on a constrained matrix tri-
factorization algorithm suggested by the same authorsZZ15.
Vliet et al. made a comparison of several integration strategies (pasting of feature matri-
ces, linear combination of distance measures or kernel functions, stacking) and classifiers to
predict breast cancer outcomevHv+12. The authors reported most success via an intermediate
strategy using a nearest mean classifier our via a late strategy using a logical OR function.
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2.5.2 Unsupervised Patient Subgroup Detection
Apart from supervised patient stratification using defined clinical endpoints (e.g. survival
times), a lot of effort has been made to detect patient sub-populations in a completely un-
supervised manner based on molecular data. An example of this approach is the detection
of four different molecular subtypes of GlioblastomaMultiforme (GBM) patients based on
gene expression data by Verhaak et al.MFB+08. As more molecular data modalities from the
same patient become available now, many authors explored the possibility of fusing these
data for discovering stronger patterns (seeCKB+14 for a review)
Akin to the case of supervised learning for patient stratification, unsupervised data fu-
sion approaches can be broadly classified into three groups, which involve early, late and
intermediate integration schemes. Early integration methods work with a joint feature ma-
trix and modify traditional clustering algorithms, such as k-means, to calculate a weight for
each data sourceCXHY13. Late integration combines patient similarity matrices obtained from
independent clusterings of distinct data types. Intermediate integration methods typically
aim for extracting common features from different data modalities combined with cluster-
ing of patients.
An example of an intermediate integration strategy is non-negative matrix factorization
(NMF)LS01. The idea behind NMF is to factorize a data matrix into a product of two ma-
trices, one indicating discriminative feature combinations between clusters and one indi-
cating cluster assignments of patients. While originally NMF was designed to work with
one data modality only, later work has extended the approach to simultaneous clustering of
several data types. For example, Zhang et al. used an extended NMF framework to cluster
385 ovarian cancer patients based on joint gene expression, DNAmethylation and miRNA
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profilesZLL+12.
Another popular intermediate integration approach is the iCluster method by Shen
et al. SOL09,SMS+12. This technique combines ideas from sparse matrix decomposition and
latent factor models and has also remarkable similarities to probabilistic PCATB99 and k-
meansDH04. Furthermore, the iCluster method can be seen as a special case of Bayesian
canonical correlation analysis with a sparsity prior for the coefficient matrixKVK13, facilitat-
ing model identifiability and interpretability. In SMS+12 the authors used iCluster to inte-
grate gene expression, DNAmethylation as well as CNV data of GlioblastomaMultiforme
(GBM) patients. The iCluster method treats information from all patients with the same
confidence, which may lead to erroneous results, if there are patients with disconcordant
information from different omics data modalities. The latter issue was taken up by Yuan
et al.YSM11, who developed a Patient Specific Data Fusion (PSDF) model, which gives dif-
ferent patients separate weights within a non-parametric Bayesian framework. A unique
aspect of PSDF is that it allows for the separation of concordant and dis-concordant signals
from patients and unlike iCluster does not force patients to cluster together. The obtained
disease subtypes via PSDF were reported to be prognostically relevant by the authors. A
limitation of the PSDFmethod is in the required data discretization, which may lead to
considerable loss of information. Similar to the PSDFmethod Kormaksson et al.KBF+12 pro-
posed a mixture-model for integrative clustering of gene expression and DNAmethylation
data. Unlike PSDF, the method does not require data discretization. However, a limitation
is the assumption of statistical independence of molecular features.
Another recent mixture model approach is the MDI (Multiple Data Integration) ap-
proach by Kirk et al.KGS+12 and Savage et al. SGG+13. Following a Bayesian non-parametric
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clustering approachMDI assumes a Dirichlet Process Prior over cluster assignments. More-
over, and in contrast to PSDF, MDI learns exact dependencies between the different data
sources as a directed acyclic graph. This implicitly results in a preference to put patients
into the same cluster, if they tend to group together in each of the different data sources.
However, at the same time each data source still retains its own clustering, reflecting the fact
that different molecular data may express partially non-concordant patient groupings. Sav-
age et al. SGG+13 used the MDI model to integrate genomic, epigenomic and transcriptomic
information of GBM patients and reported clinically relevant disease sub-types. MDI is
flexible in modelling continuous (e.g. gene expression) as well as discrete (e.g. CNVs) data.
A limitation is the assumption of statistical independence of molecular features.
Generative modelling approach, such as MDI and PSDF, require to express explicitly
the joint statistical distribution over different data modalities. This complication is avoided
in late integration techniques. Examples are Similarity Network Fusion (SNF)WMD+14 and
Multiview Genomic Data Integration (MVDA) SFF+15. These techniques use independent
clustering algorithms for each data modality and aggregate results of patient similarity ma-
trices from each data source. Thus, late integration potentially allows for incorporating
thousands of features for each data modality. Furthermore, late integration techniques are
typically more robust to small sample sizes. A limitation is the difficulty to explicitly model
dependencies between data modalities. The SNFmethod models patient similarities as net-
works with nodes representing patients. Each data modality generates its own network, and
these networks are then fused into a consensus network using a message-passing algorithm.
The authors in this way integrated gene expression, DNAmethylation as well as miRNA
profiles over five cancer datasets and performed graph clustering on the consensus network
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to identify disease subtypes. TheMVDA approach SFF+15 concatenates patient-patient sim-
ilarity matrices obtained from different data sources and then uses matrix factorization of
the concatenated matrix to come up with a consensus clustering.
Biclustering is yet another popular statistical technique for simultaneous clustering of
the rows and columns of a data matrix and has recently also been employed for data fusion.
The original method along with its modifications has since many years found several appli-
cations in biological data analysis (seeMO04 for a comprehensive review). Recently, Bunte et
al.BLSK16 developed a novel bi-clustering algorithm to cluster cancer cell lines treated with
different drugs while including CNV, DNAmethylation, mRNA, protein abundance
and exome sequencing information. The model is based on the previous work of the same
group of authors on the Group Factor Analysis ModelKVLK15. Another technique based
on biclustering has been proposed by Sun et al SBK13,SBK14. Their method is based on sparse
singular value decomposition (SSVD) and was applied to combine SNP information with
clinical data for disease subtyping and identification of subtype-specific genotype varia-
tions.
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Table 2.1: Selected Staধsধcal Learning Techniques for Personalized Medicine using Mulধple Data Sources
Method Objective modelling
Ap-
proach
Input Output AssumptionsAdvantages Limitations
Daemen
et
al.DGO+09
supervised
clinical
outcome
predic-
tion
Multiple
Kernel
Learn-
ing
mRNA,
CNV,
clinical
data
clinical
out-
come
linear
kernel
combina-
tion can
enhance
prediction
perfor-
mance
flexible
and
extend-
able
frame-
work
computationally
costly
iBAG,
Wang
et
al.WBM+13
supervised
clinical
outcome
predic-
tion
graphical
model
miRNA,
mRNA,
methyla-
tion
patient
survival
model
consistent
with bi-
ological
data and
at least
partially
identifi-
able
fully
proba-
bilistic
approach
framework
not easy
to extend;
compu-
tationally
costly
Gade
et
al.GPF+11
supervised
clinical
outcome
predic-
tion
correlation,
statis-
tical
meta-
analysis,
boosting
miRNA,
mRNA
patient
survival
miRNA-
target
predic-
tions
largely
consistent
with bi-
ological
reality
conceptually
simple
framework
not easy
to extend;
compu-
tationally
costly
Zitnik
et
al.ZZ15
supervised
clinical
outcome
predic-
tion
matrix
factor-
ization
miRNA,
PPI, GO
anno-
tation,
histo-
logical
data
chemical
in-
duced
liver
injury
biologically
relevant
infor-
mation
can be
extracted
from
linear
subspace
of the data
flexible
and
extend-
able
frame-
work, can
integrate
various
types of
informa-
tion
relies on
relations
between
biological
entities (e.g.
GO terms
and genes),
compu-
tationally
costly
Table 2.2: Selected Staধsধcal Learning Techniques for Personalized Medicine using Mulধple Data Sources
Method Objective modelling
Ap-
proach
Input Output Assumptions AdvantagesLimitations
Zhang
et
al.ZLL+12
unsupervised
disease
subgroup
identifica-
tion
matrix
factoriza-
tion
mRNA,
miRNA,
methyla-
tion
disease
sub-
types
biologically
relevant
informa-
tion can be
extracted
from linear
subspace of
the data
flexible
and
extend-
able
frame-
work
same in-
fluence of
each data
source
Shen et
al. SMS+12
unsupervised
disease
subgroup
identifica-
tion
matrix
factoriza-
tion
mRNA,
miRNA,
methyla-
tion
disease
sub-
types
biologically
relevant
informa-
tion can be
extracted
from linear
subspace of
the data
flexible
and
extend-
able
frame-
work
same in-
fluence of
each data
source
PSDF,
Yuan
et
al.YSM11
unsupervised
disease
subgroup
identifica-
tion
Bayesian
non-
parametric
(Dirich-
let
Process
Mixture
Model)
mRNA,
CNV
disease
sub-
types
model con-
sistent with
biological
data and
at least
partially
identifiable
fully
proba-
bilistic,
flexible
and
extend-
able
frame-
work
data
discretiza-
tion,
compu-
tationally
costly
MDI,
Kirk et
al.KGS+12
unsupervised
disease
subgroup
identifica-
tion
Bayesian
non-
parametric
(Dirich-
let
Process
Mixture
Model)
mRNA,
DNA
methy-
lation,
CNV
disease
sub-
types
model con-
sistent with
biological
data and
at least
partially
identifiable
fully
proba-
bilistic,
flexible
and
extend-
able
frame-
work
assumes
statistical
feature
indepen-
dence;
compu-
tationally
costly
SNFWMD+14unsupervised
disease
subgroup
identifica-
tion
patient
simi-
larity,
message
passing
mRNA,
miRNA,
DNA
methyla-
tion
disease
sub-
types
thresholding
patient-
patient
similarities
defines
subtypes
flexible
and
extend-
able
frame-
work
neglects
biological
depen-
dencies
between
data
modalities
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If I have seen further it ॾ by standing on the shoulders of
Giants.
Isaac Newton
3
Machine Learning Approaches to
PersonalizedMedicine in Glioblastoma
3.1 IDENTIREST: Identifying new therapeutic targets in Glioblastoma
As described earlier, Glioblastoma (GBM) is a brain tumor with an incidence rate of 3-4
cases per 100,000 people. GBM is the most malignant brain tumor in adults and is also
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one of the most aggressive human tumors. Tumor resection along with the use of radia-
tion and chemotherapy have a positive influence on the survival of the patients. Still, the
prognosis remains poor with a median survival of only around 14 months. Apart from the
classic characteristics of tumors, GBM has additionally a number of peculiarities that are
currently insufficiently taken into account for the diagnosis and treatment planning. Al-
though, various histological and molecular subgroups existPKC+06,VHP+10b, they are often
grouped together as one entity leading to a very heterogeneous course of the disease. In
addition, there are also a variety of cellular and functional phenotypes within tumor tis-
sue that have not been adequately classified to date. Residual tumor cells that remain be-
yond the margins of every glioblastoma (GBM) resection are believed to play an important
role in relapse of the diseaseGRS+10. These residual cells are also know to be resilient to post-
surgical therapy. These residual tumor cells have not been studied in the past and the goal
of the IDENTIREST project was the characterization of these cells with a goal to identify
new drug targets.
The project builds on the past work ofGRS+10 which concentrated on the isolation and
initial characterization of vital residual tumor cells of GBMs. It was shown that the resid-
ual cells have different properties than the routinely removed and conventionally studied
GBM cells (known also as central cells). They are e.g. migratory and proliferative active, but
have a lower content of stem cells. Moreover, the authors observed a different expression of
relevant therapeutic targets along with different response to in vitro therapy (see Fig. 3.1).
As a Pilot project, 12 paired cell samples were used to generate genome-wide transcrip-
tion profiles (using Affymetrix array). The data analysis of the transcription profiles re-
vealed that the molecular signature of residual tumor cells differs significantly from the
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Figure 3.1: Figure taken from Glas et al., 2010GRS
+10: (A) GBM ধssue taken from rouধnely-picked and convenধonally
analyzed (green). In the resecধon margin (orange), however, tumor cells (residual tumor cells) always remain in the
paধent (D). Center biopsy morphology of GBM cells. Resecধon margin (Periphery biopsy), the locaধon of the residual
tumor cells. (F) GBM cells (idenধfied and quanধfied by paধent-specific amplificaধons, here the MDM2 and CDK4
genes) can be isolated from the ধssue of the tumor center as well as the resecধon margin and accumulated to a
similar extent. This allows the comparaধve in vitro analysis of both cell populaধons.
signature of central GBM cells. 109 significantly differentialy expressed genes were found
which on applying a stricter filter criterion led to 14 candidate genes (see Fig.3.2)
A pathway enrichment analysis using the Kyoto Encyclopedia of Genes and Genomes
(KEGG, www.genome.jp/kegg/) resulted in 33 signaling cascades which are significantly
differentially active in both cell populations. Altogether, 109 significantly differently ex-
pressed genes could be specified (Figure 3.2A). By applying filter criteria, this list could be
narrowed down to 14 candidates for further analysis (Figure 3.2B). Expression of these genes
was confirmed by qPCR on a collective of five paired samples (Figure 3.2C). The distri-
bution profile of the candidate genes was shown to be stable even with prolonged in vitro
expansion of the cells (Figure 3.2D).
The functional relevance of these regionally expressed genes, which are potential targets
has also been explorative and demonstrated (Figure 3.2E and F): (i) Targets of central GBM
cells: The proliferative activity of GBM cells of the tumor center was checked via inhibi-
tion of Fibroblast growth receptor FGFR1 . Residual GBM cells that express less of this
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Figure 3.2: Figure taken from unpublished manuscript (Glass, Laurel, Cheerful, Riemenschneider, Scheffler in prepara-
ধon.)(A) Unsupervised cluster analysis of the 109 disধnctly differently expressed 109 genes in central (z) and residual
(p) GBM cells. (B) By applying filter criteria to (A), a shortlist of 14 candidate genes could be generated. (C) qPCR val-
idaধon of candidate genes on five pairs of samples (D) Stability of the profiles (cell passage was analyzed 3 vs. 17 in
vitro, underlying microarray data from passage 5). (E) Pilot experiment for FGFR1 (cell confluence determinaধon by
Cellavista®) and (F) STAT1 (measurement of metabolic acধvity by alamarBlue® assay) show that central and residual
GBM cells can be differenধally inhibited due to the different expression of the target structures (color coding of the
data : green, central GBM cells, orange, residual GBM cells)
receptor, on the other hand, were much less inhibited. (ii) Targets of Residual GBMCells:
Conversely, fludarabine15-mediated inhibition of the transcription factor STAT1 in residual
GBM cells produced significantly greater inhibition of metabolic activity than in the corre-
sponding tumor central cell samples (Figure 3.2C and F). STAT1 is expressed more strongly
in residual cells.
The goal of the IDENTIREST project was to study and analyze these residual tumor
cells in large population cohort. The aim was to then validate the results of the pilot ex-
periments, which could potentially lead to the development of novel targeted therapies.
These novel therapies would also be patient-specific and would thus lead to the goal of new
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tailor-made remedies for GBM. For this purpose, a cohort of around 270 samples coming
from around 60 patients were used. As the Primary GBM and Residual GBM samples had
widely differing properties, a new and innovative biotechnology technique was employed
(using stem cell biological technologies) to grow and expand the cells such that they could
reflect and map patient-specific properties in vitro for a longer time. It was made sure that
there were at least two tissue samples are available per patient: one from the tumor center
and one from the resection wall after completion of routine intervention. The latter sample
was then used for purification of the Residual tumor cells.
Two kinds of molecular data was available: Whole genome transcriptomics data (us-
ing Affymetrix GeneChip™Human Transcriptome Array 2.0) for around 220 samples
and SNP data for around 190 samples (using Infinium CoreExome-24 and Infinium Psych
DNAmicroarray). Apart frommolecular data, patient level clinical data was also available
like age, sex, pre and post-surgery Karnofsky Index. The clinical data has been summarized
in Fig.3.3
In the following sections we try to answer the important questions raised by the IDEN-
TIREST project. Each section describes a certain problem which was necessary to first gain
more clarity about the nature of the Peripheral Samples and secondly would lead to patient-
specific targets (based on certain biomarkers). Firstly, a set of differentially expressed genes
were identified between the central and peripheral samples (details of which follow in the
next section). Following that a significant amount of work was done by others to prioritize
these potential target genes leading to a validated set of 32 genes (the details of which have
been left out here as the work falls outside the scope of this thesis).
The present chapter tackles questions related to the nature of the samples derived from
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patients, providing algorithms for sample stratification (not patient stratification). This
in turn can be understood as providing answers to smaller parts of a much bigger puzzle
(i.e. of finding novel personalized treatments for GBM patients). The key accomplishment
of this chapter is the development of the statistical classifier which can successfully predict
the relative location of tumour recurrence from peripheral gene expression profiles. This
classifier has very important implications in the clinical management of the GBM patients.
Using the predictions of this classifier, regions of tumor recurrence could be identified in
future patients leading to more targeted adjuvant therapy.
Figure 3.3: Figure describing the clinical data from the paধents in the IDENTIREST project
3.2 Sample heterogeneity in Transcriptomics data
One of the key premises of IDENTIREST project is the existence of two kinds of cells, viz.
the central tumor cells and the residual tumour cells which are located on the immediate
periphery of the central cells (see Fig.3.4). After tumor resection, the surgeon collects sam-
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ples of both kinds from the patient. Our first task was to explore the differences between
residual tumor cells (known as periphery or P cells) and the tumour cells (the central cells or
C cells) using transcriptomics data.
For this purpose we first used the Transcriptomics data set (gene expression array). We
performed the following normalization steps: We used ‘arrayQualityMetrics’ R-packageKGH08
to perform initial data quality check. Then using the R-package ‘affy’GCBI04 probe level
summarization was performed via a median polish and background correction carried out
via RMA IBC+03 Iri03. Mapping of probe-sets to genes was based on the Affymetrix annota-
tion file, which can be downloaded from the Affymetrix web page.
After the aforementioned normalization of the raw data we looked into the expression
profiles of the 220 samples. These cells were not only P or C, but other kinds of cell types
were also included for reference. As the transcriptomic data contains around 70000 fea-
tures, PCA plots are a way to understand the heterogeneity within the sample population
on a low dimension. This is presented in Fig.3.5. As one can see from the Fig.3.5, there exist
a large heterogeneity within the cell population of Peripheral and Central Cells. The refer-
ence samples (like GBMCell lines, NPCs, Astrocytes and Neurons) are well separated from
P and C cells, however there are two clusters which contain both the Peripheral and Central
Cells.
3.3 Sample Identification using Genomics Data
Apart from the mRNA expression data, we also had access to the SNP array data for 187
samples genotyped on two Illumina arrays - Infinium CoreExome-24 and Infinium Psy-
chArray. Our focus in using the genomics data was on identifying sample characteristics
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Figure 3.4: Figure describing the origin of the peripheral and central cells
Figure 3.5: Figure describing the first two principal components of the Transcriptomics data
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based on the differences in genomic profiles for Central (C or Z) and Peripheral (P) sam-
ples. We hoped to find key differences in these two cell population. In a way, the Genomics
data served to validate our hypothesis of differences between the two kinds of cell types.
The input for our analysis was Genotype, LogR and B-allele Frequency values for 588,454
SNP locations (for 187 samples). The corresponding annotation of the SNPs on the chro-
mosome was also provided. We used open source library PennCNV-1.0.3 to identify larger
structural changes like Copy Number variations (CNVs). Approximately 25,000 CNVs
were detected using the software. Further filtering of CNVs by specifying minimum CNV
length of 50kb and minimum number of contained SNPs to 10 leaves around 16,000 CNVs.
In the next step only those CNVs which are locally associated to gene regions (within 5
kb pairs) are annotated to Genes. The 16,000 CNVs map to around 20,000 genes, this is
because one CNV could map to multiple neighbor genes. We only consider those CNVs
which show changes in at least 5 samples, also we only use those genes who have non-conflicting
CNV changes (meaning that the CNV regions that map to the same gene should all have
the same Copy Number change). This leaves us with 1070 genes with their corresponding
copy number changes.
Given this list of genes with their copy number variations in each sample, we explore two
important questions: a) Is the CNV data associated to the Peripheral/Central annotation of
the samples (from the surgeons annotation) and b) Is the CNV data associated to the gene
expression pattern if we account for the class-specific (i.e. P or C) variations. In order to
answer these questions we fit separate gene-specific generalized linear model for both ques-
tions. In a) class annotation is used as outcome variable ( P or C) accounting for Patient
IDs and gender as additional covariates apart from CNV data; in b) gene expression value is
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used as outcome variable while accounting for Patient IDs, gender and sample class (P or C)
as additional covariates apart from CNV data. We next use log-likelihood test to check the
significance of the association of the outcome variable in each case to the CNV data.
Out of the 1070 genes, 473 genes have a significant (FDR 0:01) association with Periph-
eral/Central cell types. This association can also be seen in the CNV heatmap of top 202
CNV containing genes for the 180 samples which contained CNVs in Fig.3.6
The frequency of CNV calls are also significantly different in P samples and C samples.
(p-value of 7e   04). This difference can be seen in the Frequency of CNV in P vs C sam-
ples as depicted in Fig.3.7. This hints again to the fundamentally different nature of the P
samples and the need for further exploration.
As mentioned before significant amount of work was done by other to prioritize po-
tential target genes (differentially expressed between P and C sample types) leading to a
validated set of 32 genes. We found that out of these 32 genes, 7 of them have a significant
(FDR 0:01) association (using the linear model approach described above) of the Copy
Number to their corresponding gene expression scores. We have visualized this in Fig.3.8.
The results shown in this section point to the fact that CNV data provides a valuable infor-
mation in two ways:
• Providing a molecular data modality which can be used to distinguish Peripheral and
Central samples annotation provided by the surgeon.
• Corroborating the evidence of the changes in the gene expression pattern between
the P and C cells with corresponding CNV changes which are significantly associated
(see Fig.3.8)
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Figure 3.6: Heatmap showing CNVs of selected genes for the samples which are annotated as either Peripheral or
central cell types.
59
Figure 3.7: CNV call frequency for each of 180 CNV samples. There is a significant difference between Peripheral
and Central cell types
3.4 Characterizing Samples based on Verhaak Classification
Another way to explore the differences between the Central and Peripheral cell types is to
use a known classification scheme in Glioblastoma and to classify the two cell types. The
classifier predicts a defined class for each of the samples in our project. We can then analyse
the differences of the classification results on the two different kinds of samples (P and C
samples). For this purpose, we use gene expression data described in Section 2.2. For the es-
tablished classification scheme we choose the one of Verhaak et al. 2010 which is a landmark
work in the area of stratification of samples for Glioblastoma.
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Figure 3.8: List of seven target genes which showed simultaneous associaধon of the CNV changes to expression
profiles (Leđ) as well as class annotaধon (Peripheral or Central cell types) (Right)
Verhaak et al. 2010VHP+10b established a molecular classification of Glioblastoma based on
Gene Expression profiles of 202 patient samples. The authors used the expression pattern
of 1,740 genes in a consensus average linkage hierarchical clustering (Monti et al. 2003MTMG03)
and obtained four classes based on maximum clustering stability. Further, they defined
a 840 gene signature ( 210 genes per class) using ClaNC, a nearest centroid-based classi-
fier which balances the number of genes per class (Dabney, 2006Dab05). This 840 gene set
showed the minimum cross-validation error. The four classes were named as Classical, Mes-
enchymal, Proneural and Neural. The dysregulation of each of the genes- EGFR, NF1,
and PDGFRA/IDH1 were highlighted as “defining characteristics” of the Mesenchymal,
Proneural and Neural Classes respectively. This gene signature was further used to clas-
sify samples based on a separate validation set. The reproduction of a similar gene expres-
sion pattern in the validation set was taken to be strong evidence on the reproducibility
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of their 840 gene signature. A further functional annotation of the subtypes was done
by integrating the Genomic data to identify statistically significant subtype-specific copy
number variations. The 840 gene signature and the expression profiles of 202 patients
was downloaded from the TCGA’s webpage: https://tcga-data.nci.nih.gov/docs/
publications/gbm_exp/. This data was sub-setted for only those genes which were part of
the genes present in our IDENTIREST study, thus leaving 751 genes.
The gene expression data with 180 samples and 751 genes is used for obtaining class mem-
bership probabilities for the four Verhaak classes. An Empirical Bayes method (Johnson et
al. 2007 JLR07) is first used for cross-platform normalization of the IDENTIREST dataset
with the Verhaak data set. We use the implementation of Empirical Bayes in the CONOR
package in R (Rudy et al. 2011RV11). After an additional gene wise z-score normalization,
a four class linear SVM (Schölkopf 2002 SS02) classifier is built on the basis of the cross-
platform normalized training data by Verhaak et al. The cost or regularization parameter
is chosen by minimizing the Cross Validation error across a series of cost values. The final
classifier (with probabilistic predictions) is then applied to our IDENTIREST samples, and
probabilistic predictions are made separately for C samples (see Fig.3.9) and P samples(see
Fig.3.10). The Central cells can be seen to belong to all the four Verhaak classes thus further
evidencing the fact that they are regular cancer cells with cellular heterogeneity. The behav-
ior of the P cells on the other hand is atypical of normal cancer GBM cells as they mostly
belong to the Mesenchymal subtype of the Verhaak classification (small minority belong-
ing to Neural and Classical subtypes). This behavior further points to the special nature of
the Periphery cells. It has been shown that the Mesenchymal phenotype in glioblastoma
(GBM) and other cancers drives tumor aggressiveness along with resistance to treatment,
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hence leading to therapeutic failure and often recurrence of disease.OLX+17
Figure 3.9: Results of the Verhaak Classificaধon scheme on the Central Samples with each row denoধng the probabil-
ity for belonging to that parধcular subtype.
3.5 StatisticalModelling for predicting spatial recurrence in Glioblastoma
We have established the distinct nature of Peripheral cells as compared to that of Central
cells which are cancer cells and have been shown to possess GBM cell-like properties. We
have also explored the fact that there is heterogeneity within the C-cells (see Verhaak classifi-
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Figure 3.10: Results of the Verhaak Classificaধon scheme on the Peripheral Samples with each row denoধng the
probability for belonging to that parধcular subype.
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cation results) as well as within the P-cells (see PCA plot in Fig.3.5). In this section we probe
further the heterogeneity within the P-cell population. This is also, clinically, a very rele-
vant issue: In our IDENTIREST project, many peripheral samples were collected for the
same patient. These different peripheral samples originated from different brain regions of
the patient. As we know that in most cases there is a recurrence of the GBM after a certain
time. The question we tried to answer here was whether we could predict the brain region
where the recurrence began. Fig.3.11 depicts the sample collection frommultiple regions
surrounding the initial tumor resection. This means that out of the many P sample biopsies
that we get, some will be associated with disease relapse (designated as RI samples) while
others not (designated as RU samples).
Figure 3.11: Figure depicধng the collecধon of mulধple biopsies from tumor center C vs. periphery P. The exact local-
izaধon of each biopsy is marked during iniধal phase of disease for longitudinal follow up. Ađer which they are labeled
as ’RI’ (involved site) or ’RU’ (uninvolved site)
We developed an elastic net based machine learning classier (Zou, 2005ZH05) to discrimi-
nate between RI and RU samples. The classifier takes as input the gene expression profile
in brain tissue surrounding the tumor resection area. Moreover, the information whether
a sample stems from those particular patients, from which also other tissue material are
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available, is also made use of (details are explained later). The model forecasts whether the
recurrent tumor will appear in an involved (RI) or uninvolved region(RU). Figure 3.12 pro-
vides an overview about the approach that we have taken to develop the classifier and to
validate it. Briefly, we started from an initial training cohort of 73 expression profiles from
26 patients (28 RI, 45 RU). Based on these data we evaluated and compared two different
methods (Figure 3.12A):
1. An elastic net classifier using microarray features.
2. An elastic net classifier using biological pathway activity scores based on Single Sam-
ple Gene Set Enrichment Analysis (Barbie, 2009BTB+09). Single-sample GSEA (ss-
GSEA) calculates separate enrichment scores for each sample in each gene set. Each
ssGSEA enrichment score represents the degree to which the genes in a particular
gene set are coordinately up- or down-regulated within a sample.
3.5.1 Details of Classifier Development
Both the above mentioned approaches included an initial filtering step to reduce the di-
mensionality of the data. Consequently, two different classifiers were developed. We evalu-
ated and compared both approaches within a 10 times repeated 10-fold nested cross-validation
scheme. That means we randomly split our data into 10 folds. While sequentially leaving
out 1 out of the 10 folds for testing our models the remaining 90% of the data were used for
building the two different machine learning models, as described above. Importantly, all
feature filtering was done within the cross-validation procedure.
Based on the cross-validation based evaluation we selected the model yielding a higher
area under ROC curve (AUC), which is a measure for prediction performance. 50% AUC
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Figure 3.12: Overview about the approach to develop and validate a machine learning classifier to predict the relaধve
locaধon of tumor recurrence (i.e. RI or RU).
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indicates chance level and 100% a perfect prediction. The microarray feature based classi-
fier achieved an AUC of 72%, the pathway feature based one of 75% (Figure 3.12B), which
yields a preference for the pathway feature based approach. Additional evaluation of a
pathway features based classifier with a strategy where sequentially all samples from one
of the 26 patients were left out resulted into a higher prediction performance of 87% AUC.
After pre-filtering of features, an elastic-net penalized logistic regressionZH05 was used to
build the classification model using the R package ’glmnet’FHT10 . The Elastic-net penalty
provides a mix between traditional L1 an L2 penalties with parameters, controlling their re-
spective contributions. These parameters were tuned via a leave-one-out cross-validation.
The elastic net penalized logistic regression effectively shrinks coefficients towards zero,
thus achieving a sparse model fit, i.e. selecting a subset of features. An important aspect of
our data is the fact that several samples exist from the same patient, which leads to statistical
dependencies between data samples. In order to account for this aspect, we applied a data
augmentation scheme where we added a extra binary matrix to the original data features.
This data matrix contained one column for each unique patient ID. The samples are given
the value 1 if they come from that patient, else 0. Thus, for every column, all those samples
which stem from that patient have 1s, while the other samples have 0s. Regression coeffi-
cients for the auxiliary features that had been added in order to augment the data were not
penalized in our model, i.e. were not shrunken. The resulting small set of relevant features
is henceforth referred to as “signature”. When learning the elastic-net classifier based on
microarray features we obtained a set of 14 genes while pathway features led to 4 selected
pathways. The list of these selected 4 pathways is shown in Table 3.1.
We also evaluated the pathway based classifier on a separate collection of 53 expression
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Pathway Stability Coefficient
hsa03008: Ribosome biogenesis in eukaryotes 95 0.2746625
hsa03320: PPAR signaling pathway 98 -0.5208185
hsa04512: ECM-receptor interaction 82 0.2106235
hsa00230: Purine metabolism 84 0.0856415
Table 3.1: Pathway signature discriminaধng RI and RU samples. Column “Stability” refers to the frequency by which
the corresponding pathway was selected during a 10 ধmes repeated 10-fold cross-validaধon. The frequency can
range from 1 – 100, where 100 means perfect consistency. Column “Coefficient” reflects the relaধve contribuধon of
each pathway. A larger magnitude implies more impact on model predicধons (more posiধve = more impact on RU,
more negaধve = more impact on RI).
profiles stemming from 25 patients. (20 RI, 33 RU). 16 patients had gene expression pro-
files in the validation as well as in the training cohort (the expression profiles are referred
to as primary tissue samples), however these profiles were not identical. Evaluations were
separately performed on:
• The entire sample collection
• Only primary tissues.
As is typical with transcriptomics data, initially a strong batch effect could be observed be-
tween training (containing 73 gene expression profiles) and validation data (containing 53
gene expression profiles). Correspondingly, we corrected for this effect by adding the dif-
ference of means between feature values in both datasets. Effectively, this translates the
validation set to the mean of the training set and can be understood as moment matching.
A graphical depiction is shown in Fig. 3.13.
We obtained an AUC of 80% (95% CI: 67 - 93%) for the entire sample collection and
of 88% (95% CI: 77 – 99%) for primary tissues in the validation set. Thus, we have been
able to successfully validate the multivariate pathway signature to predict the site of local
recurrence of Glioblastoma patients in this retrospective study.
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3.5.2 Interpretation and visualization of signature
All four pathways that we obtain as signature (see Table3.1) for our RI vs RU classifier have
been linked to GBM and cancer in general in the literature: The most stable feature, PPAR
signaling pathway contains the nuclear receptor transcription factor PPARγ which has been
found to be expressed in high grade gliomasEK14. Changes in ribosome biogenesis have been
linked to induce cancer by down-regulating the tumor suppression potential in cellsMTD12.
Furthermore, dysregulation of purine metabolism has been connected to the development
of tumor initiating cells in gliomaWYX+17. Finally, the ECM receptor interaction has been
shown to play a key role in the proliferation of glioma cellsUJPK09. In order to better under-
stand our four Pathway signature in terms of genes which are annotated to the respective
pathways, we visualize the fold changes of those genes in the Fig.3.14 where a total of 397
genes are shown with their fold changes (between RI and RU) along with edges connect-
ing them to the respective pathways. We have used Cytoscape SMO+03 software to visualize
Figure 3.13: The batch effect is clearly observed on the leđ between the training and validaধon data sets. On the
right is the PCA plot ađer batch correcধon
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the fold changes of the genes in these four pathways. Cytoscape is an open source software
enabling the visualization of complex biological and molecular networks.
Next, we explored the importance of the 4 Pathway signature in terms of its correla-
tion with Progression Free Survival Times (PFS) and Overall survival (OS) in GBM. For
this purpose, firstly we first selected patients from the IDENTIREST project which have
unique Central Cell biopsies. Overall, 34 patients fulfilled this criterion and had PFS and
OS information available. We use a Cox Proportional Hazard’s model (CoxPH) as imple-
mented in the ’coxph’ function in the R-package ’survival’TL15. We found that the 4
pathway activity scores were significantly related to both to PFS (p-value 0:003) and OS (p-
value 0:005) with fitted C-Index of 0:68 (for PFS) and 0:71 (for OS). Correcting for Age
and Gender as additional covariates, we find that the 4 pathway signature significantly
improves the base Cox-model (fitted with Age and Gender) in case of both PFS (p-value
0:002) and OS (p-value 0:0004). These results on the IDENTIREST samples suggest that
the pathway signature which predicts the spatial recurrence of the tumor is also related to
the PFS and OS.
Going one step further, we next used a different cohort of Verhaak et al.VHP+10a GBM
samples to check if we can ascertain the correlation of the pathway scores (as calculated by
the ’ssgsea’BTB+09 method) to the PFS and OS. 77 Verhaak patients had PFS informa-
tion and 342 had OS information. We found that in both cases the pathway signature was
significantly correlated with PFS (p-value 0:009) and OS (p-value 0:005). Moreover, after
accounting for age and gender, the 4 pathway signature resulted in significant improve-
ments in the CoxPHmodel fit for PFS (p-value 0:01) and OS (p-value 0:02). Hence, we
can say that molecular signatures predicting spatial recurrence also has prognostic value as
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measured using PFS or OS.
3.5.3 Clinical potential for the signature
To summarize, we have established the 4 pathway signature to classify RI and RU samples
from 73 expression profiles stemming from 26 patients. Additionally, we have retrospec-
tively validated the pathway signature based classifier in a cohort of 25 patients providing 53
gene expression profiles. The natural next step would be a prospective validation study.
If we are successful in prospectively validating our pathway signature based classifier, this
would open up its potential use in clinical practice as a prognostic tool. Essentially, such a
prognostic tool would be able to predict for future patients the site of recurrence based on
their spatial biopsies. Based on the predictions produced by such a prognostic tool, patients
would then be provided with targeted radiotherapy, which (hopefully) should be useful to
delay (or even stop) the progression of GBM. A clinical study would have to assess the ef-
ficacy of such targeted radiotherapy, this would involve comparing the patients who have
received targeted radiotherapy to those who receive standard of care treatment with respect
to their respective disease progressions. Such disease progressions could be measured by,
e.g., comparing the KaplanMeier curves of the two groups based on their OS of PFS (time
to next recurrence). Such a clinical study, if successful, would establish the pathway classi-
fier as a viable prognostic tool in clinical practice and this would be the future direction of
research.
In order for our 4 pathway signature based classifier to be used widely as a prognostic
tool, specific tailor made assays need to be designed. The most successful example of such
customized arrays are MammaPrint® and BluePrint® which are marketed as ‘Breast Cancer
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Recurrence andMolecular subtyping kit’ by the diagnostics company Agendia. A prod-
uct similar on those lines can also be envisioned for our pathway based classifier which
would be useful in clinical management of GBM. Although the original 70-gene signa-
tureVVDVDV+02 for breast cancer was established using microarrays, the successful clinical
application lead to the development of the Laboratory Developed Test (LDT) (essentially
a customized array) which are then also subject to FDA (or other regulatory agency’s) ap-
proval. Such approval is based on randomized prospective clinical trials validating clinical
utility of these LDTs. The development of customized arrays (and hence LDTs) raise non-
trivial challenges like mapping of the gene microarray based classifier to the new customized
array classifier (e.g., RT2 Profiler PCR Arrays fromQIAGENwhich provides measurement
of some hundreds of pathway-focused genes). Furthermore, clinical trials and regulatory
approval is a very time and cost demanding process that needs to be assessed, planned in
terms of and in relation to the differential clinical benefit of such LDTs to the GBM pa-
tients in clinical practice.
Thus, a road-map has been laid out for the future direction of the work for bringing the
RI vs RU pathway based classifier from the field of research to a commercially viable and
clinically effective prognostic subtyping toolkit.
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Figure 3.14: Graphical depicধon of the 4 Pathway signature along with the consধtuধve gene sets. All the genes annotated to the 4 Pathways,which also have
corresponding AffyIDs on the microarray, have been depicted with their respecধve fold changes
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“Doubt ॾ the origin of wisdom”
Rene Descartes
4
SBC – A novel technique for patient
stratification
4.1 Motivation for SBC
As explained earlier, the goal of personalized medicine is an individually optimized patient
treatment. This idea typically implies a stratification of patients into sufficiently homo-
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geneous sub-populations. In that context, characterization of disease sub-types is of high
relevance. Some early land-mark studies of patient stratification based on gene expression
data set (AED+00,BKH+02,VVDVDV+02,LLH+04) have generated a lot of interest in this direction.
Disease subtype identification with an emphasis on patient survival prediction, which is
highly relevant to the promise of individual therapies, can be approached using either the
molecular -omics data alone (fully unsupervised) or based entirely on patient survival data
(fully supervised) by dichotomizing the patients into predefined groups like ”low-risk” and
”high-risk” and then using standard discriminative analysis tools like support vector ma-
chines (SVM), linear discriminant analysis (LDA) or multinomial regression SRT+02 to make
predictions. The success of the supervised approach thus critically depends on the a priori
definition of patient sub-groups and the correspondence of these groups to molecular data.
Unsupervised clustering (such as hierarchical clustering -YFM+01) on the other hand fo-
cuses on discovery of molecular separable disease sub-types without any clinically moti-
vated a priori definition of patient sub-populations. Once the disease sub-types are estab-
lished a post-hoc analysis explores differences of the sub-types with respect to the clinical
outcomes. However, the aforementioned method could discover subtypes which may not
be related to survival or other clinical outcomes, as is evident inVHP+10b. This concern was
first highlighted byBT04 and later byKMC+10.
To address the shortcomings of traditional supervised and unsupervised approachesRFW+10
propose a Bayesian Infinite Mixture of Experts Model to cluster patients with respect to
their survival outcomes. Their model, in addition to determining main effects of the genes,
also gives an insight to their higher order interactions in different clusters. However, this is
achieved at the cost of discretizing continuous variables which – of course – leads to loss
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of information of continuous molecular data. Furthermore, their approach may suffer
from non-interpretability when patient groups with different survival outcomes have near
identical molecular profiles, thus failing to provide biological explanations for survival.BT04
propose a semi-supervised clustering which combines both gene expression data and clin-
ical end-point data. They first identify a set of genes that are significantly correlated with
survival time (using univariate Cox regression), then subsequently apply an unsupervised
clustering technique (Nearest Shrunken Centroids) with the obtained set of genes. Risk
predictions are made by using the principal component scores of the above mentioned set
of genes. Although successfully used in many applications,BT04 approach also has some lim-
itations. For example, the algorithm requires to pre-specify the number of disease subtypes,
which can be difficult in practice. Furthermore, the principal components of a set of genes
to predict continuous risk scores can be difficult to interpret. Finally, uni-variate gene selec-
tion can fail, if multiple genes have a joint significant effect on survival, but marginal effects
are weak.KMC+10 as a further development to this approach propose a Recursive Partition
Mixture Model (RPMM) which successively fits models with varying number of clusters
(K) and uses modified Bayesian Information Criterion to efficiently estimate K. Moreover
the model also selects the optimal gene set M. The key idea for feature and model selec-
tion is to train the model on top-ranking genes and to check the separability of the survival
curves on an independent test set. At the end that gene set M is selected which gives the
lowest possible p-value. Although computationally attractive, the results of feature selec-
tion and cluster number determination are heavily dependent on how the whole data set is
split into training and testing.
In this Chapter we try to overcome several of the above mentioned limitations of present
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techniques. More specifically our proposed Survival based Bayesian Clustering (SBC) ap-
proach has the following featuresAF17 :
• automated and fully Bayesian treatment of the number of clusters
• ranking of most discriminatory features
• integration of different -omics data types, as exemplified here via miRNA plus gene
expression data.
• prediction of class membership and survival outcomes for patients on an indepen-
dent test data.
4.2 Proposed Approach
Our SBC approach rests on the foundations of Bayesian model-based clustering and sparse
bayesian survival curve estimation. We first motivate the use of these two methodologies:
While a particular appealing property of model-based clustering (here using Gaussian mix-
tures) is to naturally deal with uncertainty regarding cluster assignment of patients, the
Bayesian framework, in addition, allows for an elegant way to circumvent the model se-
lection problem, i.e. to decide for a particular number of clusters. More specifically,in our
present work, we build on previous work in the machine learning community on Infinite
GaussianMixture Model (GMM)Ras99. Infinite GMMs are based on a Dirichlet Process
(DP) prior over parametersNea00. The DP priors define a probabilistic model for data gen-
eration and for cluster assignments. The most important characteristic of infinite GMM is
BayesianModel Averaging which allows us to estimate the posterior distribution over the
number of clusters, thus avoiding the need to compare separately fitted GMMsGR10,Nea00.
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In the past several attempts have been made to use DPmodels for clustering gene expres-
sion profiles byMS02,MYB04 and more recently byYSM11.MYB04 compare the performance of the
infinite model to the finite model case in a simulation setting and find it advantageous to
use infinite model especially in the case of high noise. Motivated by these findings and its
inherent flexibility we choose Dirichlet Process GaussianMixture Models (DPMM) for
modelling the expression profiles in our work.
One of the key innovations of the present work is the additional inclusion of cluster-
specific survival models in the DPMM.We use Accelerated Failure Time model (AFT) with
the log-normal assumptionRoy01 to model the survival or progression free survival times of
the patients. The choice of the AFTmodel as opposed to the Cox Proportional Hazards
model was made due to the ease of casting the AFTmodel in a Bayesian setting. We model
the AFT as a Bayesian LASSOPC08 to identify potential biomarkers which are related to
survival times. Apart from cluster-specific sparse survival models two further key innova-
tions in our approach are:
• Data Integration : We extend our mixture model to more than one data source (e.g.
gene expression plus miRNA expression). As opposed to existing work our approach
thus combines multi-omics and survival information to cluster patients.
• Prediction: In contrast to unsupervised clustering methods, our model can be used
to make survival as well as class predictions (sub-type) of new patients. In contrast to
supervised methods we do not need to know patient sub-types in advance.
79
4.3 MethodDetails
4.3.1 Dirichlet ProcessMixtureModel
Dirichlet Process (DP) Mixture models belong to the broad category of Bayesian Non-
Parametric methods. They allow for the inference of countable (possibly infinite) num-
ber of mixture componentsK. Dirichlet Process were first introduced byAnt74 andFer73. If
we assume X1;X2; : : :XN to beN data points drawn independently from some unknown
distribution, where Xi can be multivariate or categorical, then the Dirichlet Process Prior
models the density of Xi in the following hierarchical fashion:
Xijθi  F(θi)
θijG  G
G  DP(G0; α)
F is the conditional distribution of Xi which is parametrized by θi. G is the posterior mix-
ture distribution which is mostly marginalized when inferring DPmixture model. G0 is
the base distribution and represents prior information about the parameter values. The
parameter α is known as the concentration parameter and controls the number of clusters
that we obtain from the posterior distribution. The marginalized prior representation was
obtained byBM73 by representing it as series of conditional distributions:
θijθ1; : : : θi 1  1i  1+ α
i 1X
j=1
δ(θj) +
α
i  1+ αG0
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DP can be also be thought of as a distribution over distributions. It is known that Dirichlet
Process Prior can also be obtained by taking the limit of a finite mixture model withK, the
number of clusters going to infinity i.e. K ! 1. It was shown byNea00 that by introducing
class labels ci for each data point the old formulation ofBM73 can be re-written as following:
Xijci; θi  F(θci)
cijp Multinomial(p1; : : : ; pK)
θi  G0
p  Dirichlet(α=K; : : : ; α=K)
After taking the limitK ! 1 and integrating out the mixing proportions p, the condi-
tional distribution over the class labels ci can be formulated as:
P(ci = cjc1; : : : ; ci 1)! ni;ci  1+ α
P(ci 6= cjforallj < ijc1; : : : ; ci 1)! αi  1+ α
Dirichlet Process also defines a probabilistic model on the partition of the data points
which can be imagined by c := (c1; : : : cN):
p(cjα) = Γ(α)Γ(N+ α)
k=KY
j=1
Γ(nj + α=K)
Γ(α=K)
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For the purpose of sampling, we can sample from the conditional prior by imagining that i
is the last of theN observations :
θijθ1; : : : θ i  1N  1+ α
X
j6=i
δ(θj) +
α
N  1+ αG0
The parameter α (also know as the concentration parameter) controls the prior number of
expected clusters. FollowingGR10 it has been given an inverse gamma prior expressing the
belief that apriori we do not expect a large number of clusters.
p(α 1)  Gamma(0:5; 2)
For further details one can refer toNea00.
4.3.2 HierarchicalMultivariate GaussianModel
As a choice for the base distributionG0, we use a hierarchical GaussianModel. Our Hier-
archical Multivariate Gaussian mixture model (referred to in this work as DPMM) follows
closely the work ofGR10. The conjugate GaussianMixture model can be described with the
following sets of equations:
Xij(ci = j)  N (μj; S 1j )
(μjjSj; ξ; ρ)  N (ξ; (ρSj) 1)
where Xi indicates aD- dimensional vector of measurements (e.g. gene expression profiles)
for patient i. Furthermore, μj is the centre of cluster (or sub-type) j, described via a multi-
variate Gaussian with precision matrix Sj. The second equation constitutes a prior distri-
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bution for μj which itself is a normal distribution with expectation ξ and scaled precision
matrix ρSj. We regularize the precision matrix towards a diagonal matrixW as inBF13 :
(Sjjφ;W)  W(φ; (φW) 1)
whereW denotes a Wishart distribution with φ degrees of freedom. Empirical Bayes esti-
mates as described inGR10 are used as priors over the hyper-parameters (ξ,W etc.). We use a
conjugate Dirichlet Process GaussianMixture Model as it allows for the possible marginal-
ization of the cluster-specific parameters. More concretely, the joint distribution of the
mean μj and the precision matrix Sj follows a Normal/Wishart distribution
(μj; Sj)  NW(ξ; ρ; φ; φW)
The parameter ρ controls the strength of the dependence between the mean μj and the pre-
cision Sj; while φ controls the dependence between the hyperpriorW and precision matrix
Sj. We used the following distribution priors:
ρ  Gamma(0:25; 2)
1
φ  D+ 1  Gamma(0:5; 2=D)
As φ controls the degrees of freedom in theWishart distribution, it has been constrained
as φ > D  1. The hyper-parameters ξ andW are given priors based on the empirical Bayes
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estimates μy and Σy from the data:
W  diag(W(D;Σy=D))
ξ  N (μy;Σy)
4.3.3 Bayesian LASSO penalized Accelerated Failure TimeModel
The Accelerated Failure Time (AFT) model has been extensively used to model survival
times of cancer patients, modelling either the survival probabilities or time to recurrence
probabilitiesWei92. In its most general form an AFTmodel is given by:
log(ti) = β0 + β
TXi + εi; i = 1; : : :N
where log(ti) is the log survival time (or progression free survival), and β is the vector of re-
gression parameters. As most likely only a subset of features is truly associated to survival,
we place a Laplacian prior over βwhich effectively induces a L1 penalty on the regression
coefficients and penalizes small effects to exact zero. Following a Bayesian approach we
place a a diffuse gamma-prior on the penalty strength parameter, λ, and evaluate its pos-
terior.The hierarchical formulation of the Bayesian LassoPC08 is:
log(ti)jβ0;Xi; β; σ2  N (β0 + βTXi; σ2);
βjσ2; τ21 ; τ22 : : : ; τ2p  N (0p; σ2Dτ);
Dτ = diag(τ21 ; : : : τ2p)
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Our treatment of the censored patients follows closely to that of STV06. The key idea is to
treat the censored outcomes Ii = 0 as yet another unknown parameter wi and to use our
probabilistic model to estimate the censored survival times. We augmented the survival
times with pseudo variables wi which are defined as follows:
wi = log(ti) if censoring = FALSE
wi > log(ti) if censoring = TRUE
For the case of censoring, wi is assumed to be drawn from a left truncated normal distri-
bution, with the left truncation at the censored survival time STV06. The Bayesian LASSO
penalty amounts to placing a Laplacian prior on the coefficient matrix β of the following
form :
π(βjσ2; λ) =
pY
j=1
λ
2σ exp(λ
βj
σ )
The penalty parameter λ2 controls the level of sparsity and is given a gamma prior:
p(λ2)  Gamma(r; δ)
The values for r = 1 and δ = 1:78 were set as inPC08. The parameter σ2 was given an inverse-
gamma prior. The R-package blassowas used to sample parameters.
4.3.4 Bayesian Regularization
Our proposed SBCmodel is fully Bayesian. Within this framework, model complexity is
penalized with the help of prior distributions at several places:
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Figure 4.1: Graphical Model representaধon for SBC
• We use a Dirichlet Process prior to favour few clusters.
• We incorporate a prior for the covariance matrix of each cluster favouring sparse di-
agonal matrices.
• We use a Bayesian lasso to favour sparse cluster-specific survival regression models.
4.3.5 Model fitting via Gibbs Sampling
SBC can be depicted as a graphical model, as shown in Fig4.1. The hierarchical model for-
mulation and the use of conditionally conjugate model enables the use of a Gibbs sampling
based algorithm for parameter estimation. The cluster indicator variables cis are updated
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using the following conditional distribution for those components which have non-zero
elements i.e. n i;j > 0:
p(ci = jjc i;μj; S 1j ; β0j; βj; σ2j ; α)
/ n i;jN  1+ αN (wijβ0j + β
T
j Xi; σ
2
j )N (Xijμj; S 1j )
for all others combined we can sample from the conditional distribution as detailed below.
As the assignment of a new cluster involves marginalization over mixture model param-
eters, this integral turns out to be non-tractable in our case. In order to circumvent this
problem, we use the auxiliary variable method used in Algorithm 8 ofNea00 with the num-
ber of auxiliary variables set to two as described inGR10. The conditional distribution of a
data point to belong to a new cluster is as follows:
p(ci 6= cj8jjc i;μ; S; β0; β; σ2; α)
/ αN  1+ α
Z
N (wijβ0 + βTXi; σ2)N (Xijμ; S 1)dG0(μ; S; β0; β; σ2)
As there is overall dependence between the parameters of the Gaussian mixture model
(μ;S) and that of the BLASSO (β0; β; σ2), the above integral is not easy to solve. This
makes the overall Mixture Model non-conjugate and we resort toNea00’s auxiliary variable
approach to sample from the above distribution. The key idea is to able to approximate the
above integral’s value by drawing auxiliary parameters from the prior-distribution and con-
sidering the problem to be temporarily a finite mixture model. In our case, we found that
U = 2 auxiliary parameters are sufficient for good convergence. The model is fitted us-
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ing an alternating Gibbs update scheme for cluster-specific parameter set (μj; Sj; β0j; βj; σ2j )
and the class labels (c1; : : : cN) each of which can now be sampled from it’s conditional dis-
tribution. More details of the exact sampling algorithm can be found in Appendix B. For
our Gibbs Sampling we use 100 burn-in iterations and 200MCMC samples with samples
being drawn every 5th iteration (thinning). To assess the convergence of our MCMC chain,
we looked at the log-likelihood trace plots. To get estimates for cluster membership of pa-
tients we use the mode of marginal posterior distribution of each of the class labels from
our Gibbs sampling.
4.3.6 Feature Importance
The hierarchical formulation of the SBC allows us to define a ranking over the discrimina-
tory ability of each feature with respect to two clusters (a& b). We define the ranking ri of a
feature i as inYH11:
ri =
μia   μib
ωi
where μik is the ith component of the mean vector μ for cluster k and ωi is the i-th diagonal
element ofW. When we have more than one cluster, we calculate feature importance with
respect to every pair of clusters.
4.3.7 Data Integration
Our present model can be extended to integrate more than one -omics data source. In our
present work, we use data sources which have continuous (Gaussian) values. These are then
all modelled as described above. To combine several data sources (v = 1 : : :Q)we compare
two different strategies: a) one in which we work with independently pre-filtered feature
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sets from each of the data source X(v)i and b) one in which we perform a Canonical Corre-
lation Analysis (CCA) on the original (pre-filtered) features and then map data from each
data source on the top canonical covariates (X0(v)i ).
CCA is a classical data integration method (Hot36) which is used to extract concordant
feature sets. Each of the canonical covariates is constructed to successively explain maximal
correlation between linear feature combinations from two or more data sources. After we
obtain the feature sets from the above mentioned two methods we assume that the com-
plete model likelihood of feature sets of a patient given its cluster membership, can be fac-
torized as:
p(X(1)i ;X
(2)
i ; : : :X
(Q)
i jci = j;μ(1)j ; S(1)j ; : : :μ(Q)j ; S(Q)j )
=
QY
v=1
N ((X(v)i jμ(v)j ; S 1(v)j )
where X(v)i denotes features of the i-th patient from the v-th data source with features
which come either from a) or b). We further suppose a factorization of the AFTmode
across data sources as:
log(ti)j[X(1)i ; : : :X(Q)i ; ci = j; β(1)0j ; β(1)j ; σ2(1)j ; : : : β(Q)0j ; β(Q)j ; σ2(Q)j ]

QY
v=1
N (β(v)0j + βT(v)j X(v)i ; σ2(v)j )
This essentially means that each data source has its own cluster-specific AFTmodel as de-
scribed Section 4.3.3 and a weight that depends on the likelihood of observing the clinical
endpoint with features from that data source .The cluster indicator of a patient sample ci,
as in the one data source case, is given a Dirichlet Process Prior. We call this approach as in-
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tegrative SBC or iSBC. As an illustration, we have shown in Fig 4.2 the iSBCmodel with
Q = 3. To simplify notation, all parameters of the Hierarchical Multivariate Gaussian are
represented by Θ(v)k and those of the the Bayesian LASSO penalized AFTmodel are de-
noted by B(v)k .
Figure 4.2: Graphical Model representaধon for iSBC with Q = 3 data sources.
4.3.8 MakingModel Predictions
Given a already trained SBCmodel with parameters [θ(m)1:N ; c
(m)
1:N ] overMMCMC samples
and molecular dataX for test patient, we would like to solve two predictions problems a)
survival prediction and b) prediction of cluster membership. For the sake of simpler nota-
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tion,X is assumed to be of one specific -omics type, but the same approach also works for
multi-omics data.
Survival prediction
Expectation of the survival time for a new patient according to the SBC is a weighted aver-
age over predicted survival times from each cluster:
E[log(t)jX; θ(m)1:N ; c(m)1:N ] 
1
M
MX
m=1
CmX
j=1
(β0jm + β
T
jmX
)  vjm(X)
where Cm denotes the number of clusters found inMCMC samplem. Notably, eachMCMC
sample corresponds to one full parameter set of our model. Hence β0jm, βjm denote the
regression parameters in our AFTmodel for MCMC samplem. Moreover vjm(X) is the
weight that is dependent on the likelihood ofX to belong to cluster j for the MCMC sam-
plem . The weights vjm(X) for the discovered clusters j = 1 : : :Cm in the MCMC sample
m are proportional to their corresponding densities :
vjm(X) /
njm
N  1+ αN ((X
jμjm; S 1jm)
Apart from the already discovered clusters, the latent clusters (which do not have any data
point in them) also contribute to the survival prediction according to the DP, their corre-
sponding weight is given as:
vj(X) / αN  1+ α
Z
N ((Xjμ0; S 10 )d(G0)
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This integral is evaluated using the auxiliary variable formulation ofNea00 with number of
auxiliary variablesU = 2. The idea behind the auxiliary variables is to replace the above
integral with (and hence vj(X) by vu(X)) a density using parameters drawn from the
prior distribution. The auxiliary variables thus resemble clusters with no points assigned
to them. The weights vu(X) for these auxiliary variables are calculated using the following
density:
vu(X) / αN  1+ αN (X
jμu; S 1u )
where we sample (μu; Su), the auxiliary parameters, (u = 1; 2), from the prior distribution,
which is Normal-WishartNW conditioned on the hyper-parameters of the multivariate
Gaussian model:
(μu; Su)  NW(ξ; ρ; φ; φW)
The corresponding auxiliary parameters for the AFTmodel (β0u; βu) that are used for
survival prediction are also drawn from their prior distributionG0t given by the Bayesian
LASSO. Together with these weights the contribution for Survival prediction from the
latent classes can then be written as:
1
M
MX
m=1
2X
u=1
(β0u + β
T
uX
)  vu(X)
Cluster membership
The new data pointX is assigned a probability of belonging to the already discovered clus-
ters for them-th MCMC sample, c(m) = 1 : : :Cm, by using the following conditional proba-
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bility of the DPmodel:
p(c = jjX; θ(m)1:N ; c(m)1:N ) = b
njm
N  1+ αN (X
jμjm; S 1jm)
where njm is the number of patients in the cluster j and μjm, Sjm are the corresponding clus-
ter parameters of the Hierarchical Multivariate Gaussian model for them-th MCMC sam-
ple, b is a normalization constant. Apart from the already discovered clusters, the Dirichlet
Process prior also places non-zero probability for the test point to form a new cluster. This
probability is given by:
p(c = cnewjX; θ(1:m)1:N ; c(1:m)1:N ) = b
α
N  1+ α
Z
N (Xjμ0; S 10 )d(G0)
where (μ0; S0) are drawn from their prior distributionG0 given by the Hierarchical Mul-
tivariate GaussianModel as described above. In-order to avoid solving this integral, we
again use the auxiliary variable approach ofNea00 to approximate the above probability. The
details of the auxiliary variable approach are the same as for the above section on Survival
prediction. This means that apart from the existing classes, the patientX can form a new
cluster with the probability:
p(c = cnewjX; θ(1:m)1:N ; c(1:m)1:N ) = b
α
N  1+ αN (X
jμu; S 1u )
for auxilary variables u = 1; 2.
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Figure 4.3: Simulaধon results on the training set using SBC and the high noise scenario and D=20
4.4 Simulation Study
We investigated the performance of our Survival based Bayesian Clustering (SBC) model
in various simulation settings. We simulated molecular data as multivariate Gaussians
with non-trivial correlation structure and varying degrees of overlap using theMixSim
R-package. The package provides a list ofD dimensional cluster-specific mean vectors and
D  D cluster-specific full covariance matrices. Since SBC – as well as competing methods
– are typically applied on a pre-filtered subset of all features (10  D  60), we also investi-
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gated the robustness of our model when a certain fraction of noise features (20 percent and
50 percent of all features) were added, which did not contribute to the clustering structure.
Finally, the molecular data was obtained by concatenating the relevant and noise features.
For the survival data generation we used cluster-specific log-normal AFTmodels applied on
the molecular data and then added cluster-specific Gaussian noise.
4.4.1 Data Generation
We simulatedN = 100 data points, each for training the model and for testing it. We re-
peated the whole simulation process 10 times and compared our results with other compet-
ing approaches. We simulated the cluster-relevant features using cluster-specific parameters
(mean vector and precision matrix) employing theMixSimR packageMCM12. We have con-
ducted the simulations in two scenarios to explore the effect of noise
1. The low noise scenario where 20 percent of the features were noise (uninformative
for clustering) and there was 1 percent cluster overlap in the informative feature
space.
2. The high noise scenario where 50 percent of the features were noise (uninformative
for clustering) and there was 10 percent cluster overlap in the informative feature
space.
For the above two scenarios we use the cluster-specific parameters obtained from theMixSim
R package and generate 100 points for training and 100 points for testing. In the results pre-
sented here, we simulatedK = 2 clusters. We also used equal distribution of the data points
in both the clusters (50,50). For each cluster, we then used the informative features to gener-
ate the survival times using randomly generated values for cluster-specific (β0j; βj)
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4.4.2 Simulation results and comparisons
We initialized the model with k-means estimate by choosing kwith the help of silhouette
plots. The superior results of our SBCmodel in comparison to other methods (also in high
noise setting) demonstrate the need of integrating the survival times in clustering. For com-
parison of our SBCmodel with other competing models we used FLXmixGL08, k-means,
Mixture of Factor Analyzers(MoFA)MP00, PReMiuMLHA+13, sparse k-means (SparsKM)
and sparse hierarchical clustering (SparseHC)WT12. We give a short summary of the compet-
ing clustering methods :
1. FlXmixGL08 is a curve clustering algorithm. FlexMix implements a general frame-
work for fitting discrete mixtures of regression models. It allows the integration of
Generalized linear models and penalized models. It uses an EM algorithm to estimate
the parameters. We used FLXmix with glmnet R package for high-dimension regres-
sion. The clusters are initialized using a standard k-Means algorithm and the number
of clusters are chosen based on the Bayesian Information Criterion (BIC).
2. PReMiuMLHA+13 is a package for Bayesian clustering using a Dirichlet Process Mix-
ture Model. It allows for both continuous/discrete variables response variables but
does not deal with survival information. To implement our censored response vari-
ables, we disregarded censoring and considered the response as continuous. It also
allows to make predictions. The number of clusters are discovered automatically us-
ing Dirichlet Process prior.
3. MoFA (Mixture of Factor Analyzers)MP00 is a model-based density estimation to take
into account noise in high dimensional data sets. We set the number of factors to be
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two and selected the number of clusters using BIC.
4. SpaseHC (Sparse Hierarchical Clustering) and Sparse-KM (Sparse K-means Cluster-
ing) are two algorithms in the R package ’sparcl’ WT12. These two methods provide a
principal way to deal with noisy data. The number of clusters are optimized by maxi-
mizing the average cluster silhouette width.
5. K-Means - For the case of two data sources we created a concatenated data matrix
by joining the columns of the two data sources and running K-Means on the joint
matrix. To choose the number of clusters we looked for clusters which maximized
the average silhouette width of the clusters.
After having discovered the clustering we then fitted cluster-specific survival models using
the R package ’glmnet’.
The two measures used to compare our results were the C-indexHCP+82 and Adjusted
Rand Index. Rand Index measures the agreement between two clusterings, it ranges from
0 (no agreement) to 1 (full agreement), the adjusted Rand Index also corrects for chance
groupings and can have negative values (indicating worse than chance agreement). The
C-Index (or Concordance Index) is used to assess prediction performance in survival anal-
ysis and is akin to Area-Under-Curve (AUC) in the classification case. To compare purely
unsupervised clustering methods, such as k-means against our SBC approach with respect
to survival predictions on training data we applied a two-step strategy: first clustering and
then fitting cluster-specific survival curves using either a lasso penalized AFT or Cox model.
We call the corresponding algorithms as K-PCOX (K-means clustering followed by cluster-
specific penalized Cox regression), N-PCOX (Penalized Cox regression disregarding any
97
Figure 4.4: Likelihood trace plots during the burnin period for the low and high noise scenarios
clustering), K-PAFT (K-means clustering followed by cluster-specific penalized AFT) and
N-PAFT (Penalized AFT disregarding any clustering).
Our SBC algorithm generally achieves a higher adjusted Rand Index, C-index than com-
peting methods.
4.4.3 Assessing the convergence of the Gibbs Sampler
In-order to assess the convergence of the MCMC sampler, we use log-likelihood trace plots.
In Fig. 4.4 we show two such plots for the case of low and high noise scenarios withD =
20. In all our simulations we found 100 burn-in iterations to yield a convergent MCMC
chain. We then used 200MCMC samples for our posterior estimation (with samples being
taken every 5th iteration).
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Figure 4.5: Simulaধon results on the training set using SBC and the high noise scenario and D = 10.
Figure 4.6: Simulaধon results on the training set using SBC and the high noise scenario and D = 30.
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Figure 4.7: Simulaধon results on the training set using SBC and the high noise scenario and D = 50.
Figure 4.8: Simulaধon results on the training set using SBC and the high noise scenario and D = 60.
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4.4.4 Effect of varying dimensionD
We also varied the dimension (number of features) of the SBC, apart from theD = 20,
we tested forD = 10; 30; 50; 60 shown in Fig.4.5,4.6,4.7,4.8. As expected, increasing di-
mension and fraction of irrelevant features had a negative influence on SBC performance,
but altogether the advantage over competing methods still remained. This held true also for
detecting truly relevant features.
The results shown are for the training data set for 5 simulation repeats in each case. We
can see that the model performance worsens as we increase the dimension, it still, how-
ever, performs better than the competing methods. The reason for which the model per-
formance worsens on increasing the dimension is the following: as the SBC performs best
when the clustering information is complementary in the molecular data and in the survival
data, with increasing dimension the overall effect of the one dimensional survival informa-
tion (on the data likelihood) decreases and the SBC is influenced more by the noisy molec-
ular data at highD. We found that the SBC worked rather well on the rangeD = 20 to
D = 60 and hence this range was used for the real data set to determine the SBC signature.
4.4.5 Feature Importance from SBC model
As discussed above, our SBCmodel enables us to rank features on their ability to distin-
guish clusters. In our simulations we can compare the performance of the SBC to detect
relevant features. From our SBCmodel we can get scores for the relevance of each feature
which are either ”relevant” or ”non-relevant” and thus we can calculate the average Area
Under the curve (AUC) for this classification. This has been shown in Fig.4.9 where we
contrast this with penalized FlXmixGL08. The results represent 5 simulation repeats and
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Figure 4.9: Simulaধon results on the training set for detecধng feature importance in the low noise scenario
we restrict ourselves to the ”LowNoise scenario”. One can see a similar trend to the above
simulations with increasingD leading to a deterioration of the model performance.
4.5 Real Data
We apply our SBC approach on two gene expression cancer data sets and our iSBCmethod
on a multi-omics data set. In-order to demonstrate the predictive ability of our SBC or
iSBC approach we use 5 times repeated 5-fold cross-validation and compare its performance
with competing methods. For the biological interpretation of our method we choose to
present detailed results of one randomly chosen training-testing data-split for each of the
three real data sets. This example data-split divides each of the three data sets into equal
training-testing partitions.
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Figure 4.10: Results on the Breast Cancer data set. Box plots depict cross-validated C-indices for different methods.
4.5.1 Breast Cancer
We used the breast cancer microarray data set used inVDVHV+02 and available through the
seventyGeneDataR-package. For the clinical endpoint we used ”time to metastatis” along
with the corresponding censoring indicator for metastatis. The authors classified the data
into two groups, we call this clustering as Vijver classification (referred as VV). The 70-gene
signatureVVDVDV+02 was used to compare with our approach to stratify 295 patients in terms
of our clinical end-point. In order to reduce the dimensionality of the data we pre-filtered
genes according to two criteria: a) using the most significant p-values from univariate cox-
regression models and b) using a t-test between metastatic and non-metastatic groups. Tak-
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ing the intersection of these two ranked sets we arrive at a pre-filtered list of genes which
is subsequently referred to as ’SBC signature’. Notably, the same pre-filtering was also ap-
plied to two of the competing methods to ensure fair comparison (see below). Our SBC
approach outperformed the following competing methods for survival-prediction during
cross-validation procedure (measured using C-Index) (see Fig 4.10):
• An average linkage hierarchical clustering (HC) of patients on the training data (us-
ing the SBC signature) within the cross-validation procedure followed by k-nearest
neighbour (k-NN) predictions for the cluster membership on the test data and sur-
vival predictions by a penalized Cox regression model (pCOX). This approach was
taken in the spirit of van’t Veer et al. (abbreviated as HC+kNN).
• The same setting, but with original grouping of patients according to Vijver et al.
(VV) together with the 70 gene signature and then followed by k-NN together with
pCOX (abbreviated as VV+kNN)
• Using classification by Vijver et al. on the training and test sets and building cluster-
specific pCOXmodels (abbreviated as VV)
• Taking the first 20 principal components of the whole set of features on the training
data, within the cross-validation procedure and using a pCOX. That means test data
within the cross-validation procedure was first projected on the first 20 principal
components constructed on the training data, and then survival predictions were
performed via a pCOXmodel. (abbreviated as PrComp)
• A single L1-regularized Cox regression model (disregarding clustering) on a) the
whole set of features (ALL.pCOX) and b) on the pre-filtered SBC features (SBC.pCOX)
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Figure 4.11: Cross-validaধon results for Breast Cancer. Log-rank staধsধc is based on the recovered classes from the
SBC model on the training set
Figs.4.11,4.12 in addition indicate that SBC yields a separation of survival curves in dif-
ferent clusters that was at least as good as that obtained with competing stratification ap-
proaches (hierarchical clustering, original VV grouping). Instead of the hierarchical clus-
tering, we also tried the k-means clustering and the results were similar. Depicted in these
two figures is the test-statistic for the log-rank test comparing estimates of the hazard func-
tions associated to the detected clusters. The test statistic is constructed by calculating the
observed and expected number of events in each cluster at each observed time. A large value
of the test statistic indicates a stronger deviance from the null hypothesis of no difference in
the hazard functions of different clusters.
Next, we demonstrate the results obtained with our SBCmethod when training the
model on a randomly chosen subset of 50% of the samples. Our SBC signature for this
split comprised of 58-probe IDs. We obtained two clusters namely, ”Good Prognosis” (me-
105
Figure 4.12: Cross-validaধon results for Breast Cancer. Log-rank staধsধc is based on the predicted classes from the
SBC model on the test set.
dian time to distant metastasis 93 months) and ”Bad Prognosis” (median time to distant
metastasis 47 months). These two clusters yielded two well separated survival curves (p
=1:7e 08) on the training data set. We then used our method to predict class memberships
and survival times of patients (see convergence diagnostic plot Fig. 4.14). On the testing set
(the 50% of the samples not used for model training), this yielded two clusters which have
significant differences in their survival curves (see Fig4.16). Further investigation of the two
clusters obtained by our SBCmethod showed that the Bad prognosis group was signifi-
cantly enriched (p =2:4e  15, hypergeometric test) in the Estrogen Receptor negative (ER-)
type. ER status has been long established as risk factor for metastatic breast cancerPSDW84.
We also found significant enrichment (p =2:5e   05, hypergeometric test) of the Good
Prognosis cluster with the Luminal sub-type which has been reported to be associated with
better prognosis SPT+01. Over-representation analysis of our SBC signature with respect to
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Figure 4.13: Results on the Breast Cancer test data set with the example training-tesধng split. Predicted classes from
SBC. Crosses indicate censored outcomes. Clinical end point is ধme to metastasis.
Gene Ontology terms revealed the significant ”Protein Methyltransferase Activity” (FDR
<0:05). This process is indeed of known relevance for breast cancerKCV+03.
A further ranking of the SBC genes w.r.t. their importance for clustering indicated a
particular strong influence of E2F1 and TIMELESS. The gene E2F1 has been established to
be related to breast cancer and is even prognostic for metastasisHPB+03 while the circadian
gene TIMELESS has been postulated as a risk factor for breast cancer tumorigenesisFLZ+12.
Another important gene according to SBC was PGR (Progestrone Receptor), whose role
in breast cancer has been long knownHM78. Other noteworthy genes include Reticulon 3
(RTN3), which has been associated to cell apoptosisLLK+09, and IGFBP5, which has been
related to cell growth in breast cancer SSC+92.
The results on the training data set are presented in Figure 4.15 where the molecular dif-
ferences between the two SBC clusters are visually visible. The columns of the heat map are
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Figure 4.14: Log-likelihood trace plots for the Breast Cancer Data Set
METHOD (CLUSTERINGOR FEATURE SET TRAINING (T) p-value C-Index
CLASSIFICATION) (SIGNATURE) or PREDICTION (P) (Log Rank)
SBC SBC T 1.7e-08 0.79
SBC SBC P 1.2e-03 0.70
Table 4.1: Breast Cancer Data Set Results on the example data-split
arranged according to the log-odds ratio of belonging to the two clusters. Enrichment re-
sults of our SBC derived ”Good prognosis” and ”Bad Prognosis” classes with respect to key
factors in breast cancer progression are shown in Table4.2 and Table4.3. Gene Ontology
(GO) enrichment analysis of the SBC signature was carried out via a conditional hyper-
geometric test (R-package GOstatsFG06). Multiple-testing correction was applied usingBH95
method to control the False Discovery rate.
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Figure 4.15: SBC on Breast Cancer training set
ER positive ER negative
Bad Prognosis 19 36
Good Prognosis 88 5
Table 4.2: Results on Breast Cancer Data set: Enrichment of SBC classes with ER status
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Figure 4.16: Feature Importance and Selecধon from SBC on the Breast Cancer data set. The leđmost column repre-
sents importance of feature on molecular data clustering, the two right columns represent strength of associaধon to
cluster specific survival ধmes. Darker colours imply stronger effects.
Luminal Basal ERBB2 Normal
Bad Prognosis 19 25 11 0
Good Prognosis 67 1 11 14
Table 4.3: Results on Breast Cancer Data set:Associaধon of SBC classes with breast cancer sub-types
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Figure 4.17: Results on the Glioblastoma I data set. Box plots depict cross-validated C-indices for different methods.
4.5.2 Glioblastoma I (Verhaak et al.)
We also applied our SBCmodel on the GlioblastomaMultiforme (GBM) microarray data
fromVHP+10b. The data were downloaded from https://tcga-data.nci.nih.gov/docs/
publications/gbm_exp/.
We considered the ”overall survival” as the clinical endpoint in our analysis. Overall, 196
patients (with survival information) were selected along with the original 840 geneVHP+10b
signature which we used for comparison (henceforth known as the Verhaak signature). Us-
ing only the training data we filtered features based on their p-values from uni-variate Cox
Regression models and chose the top genes as our SBC signature. For the Cross-validation
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we used the same technique to arrive at the SBCmodel within each of the cross-validation
loops. Our method was able to predict survival better than the following methods (see
Fig.4.17):
• A k-means (kM) clustering of patients on the training data (using the SBC signature)
and a combination of k-nearest neighbour cluster assignment followed by a cluster
specific penalized Cox regression. (abbreviated as kM+KNN)
• Using the original 840 gene signature of Verhaak et al. and their classification (VK)
we trained a k-nearest neighbour model for prediction. We then used this classifica-
tion to build clustered pCOXmodels (abbreviated as VK +kNN)
• The PrComp, ALL.pCOX and SBC.pCOX, as defined above.
In addition, Figs. 4.18 and 4.19 indicate a better separation of survival curves with SBC than
achieved by original VK stratification, VK + kNN and kM+KNN.
For our example data-split we chose top 47 genes as the SBC signature and trained our
SBCmodel. Using that we discovered four distinct clusters (see convergence diagnostic plot
in Fig.4.21) with unequal numbers of patients (10, 5, 25, 58). These clusters showed molecu-
lar differences as well as significantly different survival curves also on the test set (Fig.4.20).
We referred to the four clusters as ”Good”,”GoodModerate”,”BadModerate” and ”Worst”
based on their respective mean survival times (830 days, 626 days, 380 days, 180 days). Look-
ing at the patients in the ”Best” prognosis cluster we find a high enrichment (p=3:5e   05,
hypergeometric test) in the ”Proneural” GBM sub-type defined by Verhaak et al. which
has been reported in the literature to be linked with better survivalCGL+10. As in the breast
cancer data set, we again computed the feature importance of the SBC signature, one par-
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ticular gene which has a higher contribution across all cluster comparisons (see Fig.4.22) is
the ”Programmed cell death 6” or PDCD6 gene. It has been known for its proapoptotic
function and is thought to be involved in survival pathways in cancer SXF+12. Another inter-
esting gene, which is assigned a high relevance by our method is TUSC4. TUSC4 has been
established as a tumour suppressor gene regulating BRCA1 stabilityPL14. BRCA1 expression
has been reported as a biomarker for GBM prognosisVWC+15.
For the example data-split, we also report in Table 4.4 our results. We again use the log-
likelihood trace plot to assess the convergence of our Gibbs sampling iterations as can be
seen in Fig.4.21
METHOD (CLUSTERING or FEATURE SET TRAINING (T) or p-value C-Index
Verhaak classification) (SIGNATURE) Prediction (P) (Log-rank)
SBC SBC T 5.3e-05 0.68
SBC SBC P 3e-02 0.56
Table 4.4: Glioblastoma I data set results for example data-split
There is a significant association between clusters discovered by our SBC and the ones re-
ported by Verhaak et al., see Table 4.5 (p=3:5e 05, χ2 test). We also note that the Best prog-
nosis class exclusively contained samples from the Proneural Verhaak GBM class while the
GoodModerate prognosis class was split between Classical andMesenchymal sub-types.
To better understand our SBC signature we plot the feature importance of all the genes
Classical Mesenchymal Neural Proneural
Best Prognosis 0 0 0 10
Worst Prognosis 0 2 2 1
GoodModerate Prognosis 7 12 1 5
BadModerate Prognosis 19 15 15 12
Table 4.5: Results on Glioblastoma I: Associaধon of SBC classes with GBM Verhaak sub-types
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Figure 4.18: Cross-validaধon results for GBM I. Log-rank staধsধc is based on the recovered classes from the SBC
model on the training set.
Figure 4.19: Cross-validaধon results for GBM I. Log-rank staধsধc is based on the predicted classes from the SBC
model on the test set.
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Figure 4.20: Results on Glioblastoma I test data set with example training-tesধng split. Predicted classes from SBC.
Crosses indicate censored outcomes. Clinical end-point is overall survival.
Figure 4.21: Log-likelihood trace plots for the Glioblastoma I Set
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Figure 4.22: Results on Glioblastoma I (SBC):Feature importance of the SBC signature on the GBM-Verhaak data set
in discriminaধng respecধve clusters
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in our SBC signature to distinguish between different clusters in Fig. 4.22. Some genes
which have higher contributions across all cluster comparisons (shown by a darker color in
the heatmap in Fig. 4.22) were investigated to reveal interesting biological functions. Apart
from the above mentioned genes, the gene SLC25A38 which is a member of the SLC25 gene
family and also plays a prominent role as a SBC signature gene has been reported to sup-
press cell growth in human gliomasWFS+11.
4.5.3 Glioblastoma II (TCGA-GBM)
We illustrate the application of our iSBCmodel on an alternative GBM dataset from The
Cancer Genome Atlas (TCGA). We considered mRNA and miRNA expression and down-
loaded the data from https://tcga-data.nci.nih.gov/tcga/. ”Overall survival” was
considered as the clinical end-point. 189 patients were considered, only those patients were
included which were part of our earlier Glioblastoma I study. This was done so that we
could compare benefits of data integration on a consistent data set. For our iSBCmethod
we perform the same type of pre-filtering on the training data as described before for Glioblas-
toma I data set. Again we compared our two methods (iSBC and CCA pre-processed iSBC
referred as C.iSBC) within a 5 times repeated 5-fold cross-validation procedure against:
• A combination of k-nearest neighbour cluster assignment followed by a cluster spe-
cific penalized Cox regression (abbreviated as KMkN) using the SBC signature with
the concatenated matrix of mRNA and miRNA expression profiles for each patient.
When CCA features are used the method is referred to as C.KMkN.
• The PrCompmethod, as defined above but this time applied to the concatenated
data matrix of gene and miRNA expression profiles.
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Figure 4.23: Results on the Glioblastoma II data set. Boxplots depict cross-validated C-indices for different methods.
• Single (disregarding clustering) Penalized Cox regression applied on the concatenated
matrix with all the features, referred to as A.pCOX.When SBC features are used, it is
referred to as B.pCOX.While when CCA features are used we refer to it as C.pCOX.
Our results (Fig.4.28) indicate at least as good prediction performance with our iSBC
and C.iSBCmethods than with competing ones (PrComp). At the same time Figs. 4.24
and 4.25 show that our methods separated survival curves better (after predicting cluster
membership of test patients) than a k-means clustering approach or k-means plus kNN
cluster membership predictions.
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Figure 4.24: Cross-validaধon results for GBM II.Log-rank staধsধc is based on the predicted classes from the iSBC
model on the test set
Figure 4.25: Cross-validaধon results for GBM II. Log-rank staধsধc is based on the recovered classes from the iSBC
model on the training set
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Delving deeper in the example data-split we selected 31 top ranking mRNAs and the top
31 miRNA probes as our iSBC signature. We then applied our iSBCmethod once with and
once without projecting data on the top 10 canonical covariates. The CCA pre-processing
leads to slight increase in the survival prediction (Fig. 4.28). In the following part we focus
our discussion on the solution obtained without CCA preprocessing. Application of our
iSBC approach lead to the discovery of 4 clusters (we call them, as before, ”Worst”,”Good
Moderate”,”BadModerate”,”Best” based on the prognosis) of unequal number of patients
(2, 27, 54, 13). The clusters from our iSBC still result in clearly separable survival curves
on both training and test data sets (see Fig.4.26). We further investigated cluster-specific
enrichment with respect to somatic mutations. The mutation pattern found in genes in-
cluded in our model is significantly related to the iSBC derived clusters (p = 1e   05,
χ2-test). An interesting observation was the mutual exclusive mutation pattern of TP53
and PTEN genes among the iSBC clusters, meaning that if TP53 was found mutated in one
iSBC cluster, PTENwas never mutated in that cluster and vice-versa. This mutual exclu-
sivity has also been reported in literatureKGM+02. Over-representation analysis of the iSBC
signature revealed the significant Gene Ontology term ”negative regulation of G1/S transi-
tion of mitotic cell cycle” (FDR <0:05). This is highly interesting because cancer cells have
an over-active cell cycle, leading to proliferation and hinting at possible mechanism for can-
cer progression. Looking at the most discriminatory features from our iSBCmodel (see
Figs.4.28,4.29), we find that one important mRNA iSBC feature is ”developmentally reg-
ulated GTP-binding protein 2” or DRG2 gene which has been shown to induce apoptosis
in cancer cells Jyx+12. Another interesting and discriminatory gene is β-catenin (CTNNB1),
which is a key protein in the Wnt signaling pathway. Deregulation of the Wnt pathway has
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been associated with various cancers, including GBMLLA+16. Another discriminatory gene
identified by iSBC is ADAM22, which has been shown to be under-expressed in high-grade
gliomasGNP+06. An important miRNA feature miR-661 is known to activate the p53 path-
way and suppresses tumour progressionHBPO14. Furthermore we found miR-675, which has
been linked to Gliomas SWL+14 while miR-637 has been shown to inhibit tumorigenesis in
various cancer typesZHF+11 and is discussed as a prognostic marker in gliomasQSL+15. For the
example data-split, we report in Table 4.6 our results. We again use the log-likelihood trace
plot to assess the convergence of our Gibbs sampling iterations as can be seen in Fig.4.27.
Our iSBC resulted in significantly different survival curves also on the test set (Fig.4.26)
We conducted a cluster-specific somatic mutation enrichment analysis. For this purpose
we looked for genes (which are part of our iSBC signature) which show cluster-specific so-
matic mutations. Somatic mutation data was only available for 23 patients out of 96 train-
ing patients. We obtained the mRNA signature from the SBCmodel, moreover miRNAs
were also mapped to their gene targets using the ’multiMiR’ package in RRKT+14. 57 unique
genes were identified in this manner. 55 out of the 57 genes show the same pattern illus-
trated in Table4.7 where all of them showmutation exclusively in the best prognosis cluster
of SBC. The interesting case is that of TP53 and PTEN genes which show a mutual exclu-
sive behavior of somatic mutation as shown in Table 4.8 and Table 4.9.
In a similar manner as in GBM-Verhaak data set we plotted the feature importance of
the mRNA and miRNA SBC signature in Fig.4.28 and Fig.4.29. We also explored features
which had more contributions with respect to others (shown by darker colours in Fig.4.28
and Fig.4.29).
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Figure 4.26: Results on Glioblastoma II data set with example training-tesধng split. Predicted classes from iSBC on
the test set. Crosses indicate censored outcomes. Clinical end-point is overall survival.
METHOD FEATURE SET TRAINING (T) or p-value C-index
(SIGNATURE) PREDICTION (P) Log-rank test
iSBC iSBC T 6e-04 0.70
iSBC iSBC P 1e-02 0.52
Table 4.6: TCGA-GBM data set results for example data-split
Worst GoodModerate BadModerate Best
Mutated 0 0 0 4
Non mutated 0 6 13 0
Table 4.7: Results on Glioblastoma II (iSBC): Number of somaধc mutaধons across iSBC defined clusters for signature
genes except TP53 and PTEN
Worst GoodModerate BadModerate Best
Mutated 0 0 13 4
Non mutated 0 6 0 0
Table 4.8: Results on Glioblastoma II (iSBC):Number of somaধc mutaধons across SBC defined clusters for TP53
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Figure 4.27: Log-likelihood trace plots for the Glioblastoma II Set
Worst GoodModerate BadModerate Best
Mutated 0 6 13 0
Non mutated 0 0 0 4
Table 4.9: Results on Glioblastoma II (iSBC): Number of somaধc mutaধons across SBC defined clusters for PTEN
Data Set Time (in minutes) Iterations(Burn-In + Gibbs Samples)
Breast Cancer 144 (100 + 200)
GBM I 83 (100 + 200)
GBM II 120 (100+ 200)
Table 4.10: Actual running ধmes for SBC/iSBC on Real Data Sets
4.6 Running Times for SBC and iSBC
We present the actual running times of the SBC on the three data sets. We used 11.7 GB
Intel 64 bit Xeon (R) 4x2.66 Ghz processor in Table 3.10.
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Figure 4.28: Results on Glioblastoma II (iSBC): Feature importance of the SBC signature on TCGA-GBM gene expres-
sion in discriminaধng respecধve clusters
124
Figure 4.29: Results on Glioblastoma II (iSBC):Feature importance of the SBC signature on TCGA-GBM mi-RNA
expression in discriminaধng respecধve clusters
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4.7 Effect of Survival Data on SBC
4.7.1 Hierarchical Dirichlet ProcessMixtureModel
SBC distinguishes itself from traditional clustering algorithms for patient level microarray
data by including clinical end-points as a very important source of information. In this sec-
tion we explored the scenario when we ignore the clinical end-point information and use
a very similar Hierarchical Dirichlet Process Mixture Model (hDPMM) (as shown graphi-
cally in Fig.4.30) to cluster the patients based on just their molecular profiles (gene expres-
sion). The difference between SBC and hDPMM is the absence of parameters for mod-
elling the survival information in hDPMM.We can also make predictions from hDPMM
in a very similar manner as described for SBC.
For the sake of comparability, we used the corresponding SBC signatures as the feature
set for the Breast Cancer data set and Glioblastoma I data set. A survival model (penalized
Cox PH) is then fitted on top the clustering obtained above to stratify the survival curves
and to make predictions.
4.7.2 Breast Cancer Data Set
The hDPMMmodel on the breast cancer data set yields no clusters. The results are pre-
sented in Table 4.11 As can be seen, stratifying patients according to the SBC yields much
better predictions for survival than using hDPMM. Thus we can conclude that survival in-
formation plays a vital role in obtaining the ”Good prognosis” and ”Bad prognosis” clusters
which were obtained from our original SBCmodel.
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Figure 4.30: Graphical Model representaধon for hDPMM
4.7.3 Glioblastoma I Data Set
The application of the hDPMMmodel on the Gliobalstoma I data set yields 3 clusters, one
which contains the majority of the data points. The three clusters contain 94,3 and 1 data
points respectively for the training data set. For the prediction, the hDPMMplaces all the
test points in one cluster. The results comparing hDPMMwith SBC are presented in Table
4.12. Again, we can make a strong case that stratifying patients according to the SBC yields
much better predictions for survival than using hDPMM and that the original 4 clusters
obtained from the SBCmodel are heavily influenced by the clinical end-points.
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METHOD FEATURE SET TRAINING (T) p-value C-Index
(SIGNATURE) or PREDICTION (P) (Log Rank)
SBC SBC T 1.7e-08 0.79
hDPMM SBC T NA 0.78
SBC SBC P 1.2e-03 0.70
hDPMM SBC P NA 0.61
Table 4.11: Breast Cancer Data Set Results with hDPMM
METHOD FEATURE SET TRAINING (T) p-value C-Index
(SIGNATURE) or PREDICTION (P) (Log Rank)
SBC SBC T 5.3e-05 0.68
hDPMM SBC T 0.90 0.73
SBC SBC P 3e-02 0.56
hDPMM SBC P NA 0.50
Table 4.12: Glioblastoma I Data Set Results with hDPMM
4.8 Effect of CCA pre-processing on iSBC
4.8.1 Glioblastoma II Data Set
Here we report the results for CCA pre-processed iSBC on the example training-testing
split for GBMII data. We used a non-penalized CCA approach to pre-process the Glioblas-
toma II Data set with the initial set of 31 mRNA and 31 miRNAs. We chose the top 10
Canonical Correlates and obtained the corresponding transformed data matrices for mRNA
and miRNA each now containing 10 features each. The results on this transformed Glioblas-
toma II data set are shown in Table 4.13 which showmarginal benefits on the prediction
performance of the integrative SBCmodel using features derived from applying CCA to
our SBC signature data sets. We still get four clusters as before with 57, 18, 15 and 6 data
points respectively. Furthermore, we obtain feature importance for our new set of fea-
tures (as shown in Fig. 4.33 and Fig.4.34) and plot the factor loading matrices in Fig.4.31
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METHOD FEATURE SET TRAINING (T) p-value C-Index
(SIGNATURE) or PREDICTION (P) (Log Rank)
iSBC SBC T 6e-04 0.70
iSBC CCA T 1e-03 0.68
iSBC SBC P 1e-02 0.52
iSBC CCA P 1e-02 0.54
Table 4.13: Glioblastoma II Data Set Results with new feature sets derived from CCA
and Fig.4.32. The corresponding correlation values for the features are also shown.
4.9 Conclusion
In this Chapter we have introduced a novel fully Bayesian clustering algorithm (SBC) which
takes in clinical end-points of patients along with heterogeneous -omics data to perform
two tasks in one - a) patient sub-group identification on training data and b) prediction of
patient sub-group and survival time on testing data. Our method was based on the mo-
tivation of discovering clusters of patients using their distinct molecular signatures and
strong survival curve separability. Another important motivation was the predictive utility
of our approach along with biological interpretability. We have shown with simulations
and real data that our method outperforms ad-hoc algorithms like k-means followed by
fitting cluster-specific survival models. Furthermore, our SBC yields clearly better results
than a hierarchical Gaussian DPMMwithout survival information, indicating the relevance
of the clinical outcome in our model. We believe the ability of SBC to identify patient-
subgroups differing in survival constitutes an advantage compared to existing approaches
likeVVDVDV+02,VHP+10b). Furthermore, SBC is principally able to take into account more than
-omics data source. Our assumed cluster specific factorization of the complete likelihood
essentially weighs features inversely to their noise level. The CCA preprocessing approach
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explored here is a refinement in that context, which could potentially also allow for com-
bining discrete with continuous data types, as e.g. shown inWTH09. In future research we
want to explore this aspect further and see, how CCA or similar latent factor approaches
could be integrated better into our SBCmethod.
From a statistical point of view SBC is a coherent clustering scheme which groups data
points based on their similarities to each other and their similarities to their (possibly) cen-
sored response variable. We have also used penalized estimation of the parameters which
allows us to deal with n < p problem, casting it in a Bayesian hierarchical setting. Our
simulation results point to the superiority of our method in comparison to other state-of-
the art techniques. On real data we have shown the ability of SBC to discover and predict
hitherto unknown clusters which also show distinct progression patterns. Notably, the run
time of our method for these applications varied between 1.5 to2h, which appears prac-
tically affordable. Of course, larger datasets are expected to require longer Gibbs sampling
and thus more computation time. In practice it is thus recommended to reduce the num-
ber of features before applying SBC.
One of they key challenges for any clustering algorithm for biological data is to explore
the biological underpinnings of the obtained clusters. In this regard we have found that
certain sub-types from our model are particularly enriched in certain biological markers (for
example ER status for breast cancer) and also correlate strongly with some sub-types in the
well established classification schemes for example of SPT+01,VHP+10b . Altogether we see SBC
as a step towards a more clinically relevant dissection of patient heterogeneity.
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Figure 4.31: Factor Loading Matrix between CCA features and the original SBC mRNA signature. Canonical covari-
ates are named as CC1-xx to CC10-xx, where ‘xx’ indicates the respecধve canonical correlaধon
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Figure 4.32: Factor Loading Matrix between CCA features and the original SBC miRNA signature. Canonical covari-
ates are named as CC1-xx to CC10-xx, where ‘xx’ indicates the respecধve canonical correlaধon.
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Figure 4.33: Feature Importance of the new CCA features derived from the mRNA-SBC signature.Canonical covari-
ates are named as CC1-xx to CC10-xx, where ‘xx’ indicates the respecধve canonical correlaধon
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Figure 4.34: Feature Importance of the new CCA features derived from the miRNA-SBC signature. Canonical covari-
ates are named as CC1-xx to CC10-xx, where ‘xx’ indicates the respecধve canonical correlaধon
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“The mind ॾ not only capable of knowing [innate ideॼ],
but further of finding them in itself; and if it had only
the simple capacity to receive knowledge it would not be
the source of necessary truth”
GottfriedWilhelm Leibniz
5
Applications of SBC to IDENTIREST data
As explained in Chapter 4, Survival based Bayesian Clustering (SBC) potentially provides
a clinically relevant method for dissecting unknown heterogeneity at sample and patient
level. One of the goals in the IDENTIREST project was also to better understand the het-
erogeneity of the samples which could be clinically meaningful. For this purpose, we apply
our SBCmethod on the cohort of samples from the IDENTIREST project. In the first part
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of this chapter, we use the SBCmodel trained on the Verhaak cohort to make predictions
on IDENTIREST Central Samples. In the second part we use a modified version of SBC
(hDPMM) to explore the heterogeneity in the entire cohort of IDENTIREST samples (Pe-
ripheral and Central samples) in an unbiased way.
5.1 Predictions of SBC on Central Samples
In Chapter 4, we had trained our SBCmodel on Glioblastoma patients from the Verhaak
cohortVHP+10a with the goal to stratify GBM patients with respect to their molecular pro-
files as well as their overall survival times. To recapitulate: Using the cohort of 98 patients,
we had trained our SBCmodel based on the 47 gene signature to obtain 4 different patient
strata (we referred the strata as following: Cluster1 or Good Prognosis, Cluster 2 or Good
Moderate prognosis, Cluster 3 as BadModerate prognosis and Cluster 4 as Bad Prognosis)
(see Section 4.5.2). Also, in the same section we used 98 other samples from the Verhaak
cohort as validation set and obtained SBC predictions. The predictions of the SBC led to 4
predicted strata which were significantly separated in their Overall Survival (OS) curves.
We now use this trained SBCmodel on the Verhaak cohort to make predictions on the
IDENTIREST cohort of patients. For this purpose, we use only those IDENTIREST pa-
tients which have unique Central Sample biopsy along with overall survival information.
The rationale behind the choice of central samples is as follows: As has been repeatedly
shown in Chapter 3 (Sections 2 & 3), Central samples are molecularly distinct from the Pe-
ripheral samples and can be considered similar to GBM cancer samples. This hypothesis
is further strengthened in Chapter 3 (Section 4) where Central Samples were satisfactorily
classified in the four molecular subtypes defined by Verhaak et al. while the Periphery sam-
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ples tend to fall predominantly into oneMesenchymal class. The choice of patients which
have unique Central Samples is made to avoid the problem (as mentioned in the last sec-
tion) of aggregating multiple samples for the same patient (which is necessary for the appli-
cation of SBC). This leaves us with 37 Central samples.
Out of the 47 gene SBC signature, expression values for 7 genes were not available in the
IDENTIREST samples. Hence, we used the R-package ’impute’HTN+11 to perform impu-
tation of the gene expression values based on its k-Nearest Neighbors. Next, we corrected
for the batch effect between the 98 sample Verhaak data set and 37 sample IDENTIREST
cohort. We achieve this batch effect correction by simply adding the difference of means be-
tween feature values in both data sets, this means that the IDENTIREST validation dataset
is translated to the mean of the Verhaak training set. This is the same technique that we
adopted in Chapter 3 (Section 5) and its graphical depiction can be seen in Fig. 5.1. After
imputation and batch correction we are ready to make predictions on the IDENTIREST
samples (based on the gene expression and overall survival data).
The SBC predicts 3 different strata for the 37 Central samples, with 25 patients belong-
ing to Cluster 4 (or GoodModerate prognosis), 7 samples belonging to Cluster 3 (or Bad
Moderate Prognosis) while 5 samples belong to Cluster 2 (or Bad Prognosis group). The
OS KaplanMeier curves are significantly separated (p-value of 4e   03). The PCA plot
along with predicted classes for the 37 Central IDENTIREST samples is shown in Fig.5.2,
along with the corresponding KaplanMeier curves. The predicted C-Index on the IDEN-
TIREST cohort was 0.56 (similar to that obtained on the Verhaak prediction cohort, see
Chapter 4).
In order to further validate the prediction clusters on the IDENTIREST cohort, we use
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the CNV (genomics) data for the 37 samples to check for significant differences. One im-
portant characteristic of each of the genomic samples is whether it contains GBM-specific
genomic alterations or not. These GBM-specific alterations can be of many types, a de-
tailed description is provided in Appendix C. Thus the samples were divided into a) those
having typical GBMmutations and b) those not having typical GBMmutation and c) oth-
ers. Many samples within the IDENTIREST cohort exhibit typical GBM genomic muta-
tions and other do not. We looked whether certain predicted SBC clusters were enriched
in typical GBMmutations containing samples. Results can be seen in Table 5.1. There is
significant association between the predicted SBC classes and Typical GBMmutation sta-
tus (p-value 1e   03, χ2 test). All samples in the predicted Bad prognosis group contained
Typical GBMmutations. We further looked into the CNV data for the 1070 genes (which
were selected in Chapter 3, Section3). We ask the question whether the CNV data is asso-
ciated with predicted SBC class labels. We fit gene-specific generalized linear models to the
predicted SBC cluster label with gender, age as additional covariates apart from CNV data.
Out of the 1070 genes, 43 genes have significant (FDR 0:01) association with predicted SBC
class labels. This association can also be seen in the CNV heatmap of the 43 genes for the 37
IDENTIREST samples in Fig. 5.3.
We further investigated the relationship between the gene expression of the 47 SBC sig-
nature and the 43 CNV genes which showed significant association to the predicted SBC
cluster. There is no overlap between these two sets of genes, so we investigated the 43 CNV
genes for their expression. Out of the 43 CNV genes, 18 of them showed a strong associa-
tion (FDR 0:01) between their gene expression values and copy number changes. This asso-
ciation was established, as before, by fitting gene-specific linear models to the outcome vari-
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able of gene expression with CNV, age, gender being the covariates. This subset of 18 genes
thus shows consistent patterns of gene expression and CNVwith respect to the predicted
SBC clusters as shown in Fig. 5.4. After establishing consistent information in CNV and
gene expression data in the 18 aforementioned genes, we checked for correlation of these
18 CNV genes and the 47 SBC gene signature. This correlation has been plotted in Fig.5.5.
65% of the correlations shown are significant (FDR 0:05), these significant correlations
represent trans-effects of CNVs . Thus we can make a strong point that there is a strong
connection 47 SBC gene signature and the 43 CNV genes which were used to validate the
clustering.
Thus, we have been able to validate the results of the SBCmodel trained on the Verhaak
cohort of 98 samples on the independent validation set of our IDENTIREST cohort. We
not only get significantly different predicted cluster-specific OS curves, but also these clus-
ters are interpretable using CNV data. To summarize, we have used both the gene expres-
sion as well as CNV data for the IDENTIREST cohort of Central samples to validate the
original SBCmodel trained on the Verhaak cohort.
With Typical Without Typical
GBMmutations GBMmutations
Cluster 3 BadModerate Prognosis 0 7
Cluster 2 Bad Prognosis 5 0
Cluster 4 GoodModerate Prognosis 12 13
Table 5.1: Results on CNV data for SBC predicted classes on IDENTIREST Central Samples
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Figure 5.1: The batch effect is clearly observed on the leđ between the training and validaধon data sets. On the right
is the PCA plot ađer batch correcধon
Figure 5.2: Results of predicধon of SBC model on Central Cells. The leđ figure shows a PCA of the gene expression
data of the Central Cells with three predicted classes. The right figure shows the different KM curves with the log-
rank p-value of the predicted strata
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Figure 5.3: Results of interpretaধon of predicted SBC clusters using CNV data. The heatmap shows the CNVs of top
43 associated genes. The central IDENTIREST samples are arranged according to hierarchical clustering. Labels on
the leđ are SBC predicted clusters.
Figure 5.4: Associaধon between CNV data and gene expression profiles. Both leđ and right figures have samples
arranged according to hierarchical clustering in the same order. Leđ figure shows the CNV changes while the right
figure shows the gene expression.
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Figure 5.5: Correlaধon between gene expression values of the 18 CNV genes (on the rows) and 47 SBC signature
genes.
5.2 Modelling sample heterogeneity using h-DPMM
In this section we make an attempt at exploring the Periphery and Central IDENTIREST
samples heterogeneity in a more unbiased way. In Chapter 3 (Section 3.2) we have pre-
sented the heterogeneity present within the transcriptomics data and later on explored the
Periphery samples in greater detail (see Section 3.5). Here we use a variation of SBC algo-
rithm, h-DPMM to explore this heterogeneity (h-DPMM is described in the Chapter 4 and
reproduced in Fig.5.6). As SBC normally works in the case of one sample per patient (with
a corresponding unique clinical end-point) multiple samples from the same patient pose
a challenge to SBCmodel. We believe that hDPMMmodel retains some of the strengths
of the SBCmodel and is a potent tool to explore heterogeneity in the gene expression pro-
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files of the samples. As the h-DPMM does not use survival data, we avoid the problem of
modelling samples with different molecular data yet having the same survival time as they
belong to the same patient.
Figure 5.6: Graphical Model representaধon for hDPMM
The microarray data chosen contained ALL the 260 IDENTIREST samples along with
ALL 27,148 microarray Features which could be annotated. An unbiased filter based ap-
proach was taken to come up with a set of signature genes (50). These were genes top 50
genes selected on the basis of their moderated F-statistics from R-package limma . The
F-statistic measures the variations of the genes without any specific contrast. Our model
hDPMM discovers 3 distinct clusters (Average Silhouette Index 0.23) in these 260 patients
based on their expression of 50 gene signature. As one can qualitatively see in Fig.5.7, the
clusters obtained from hDPMM are associated to the P and C cell types. This analysis
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shows that results from our model confirm the initial hypothesis about the differences be-
tween the Peripheral and Central cell types. We note that this heterogeneity was obtained
without taking the survival times (or PFS) of the patients into account, also the the list of
50 features was obtained without any reference to any contrast.
Figure 5.7: Results of hDPMM on 220 IDENTIREST samples presented in terms of PCA plots. On the leđ the labels
come from classificaধon of th cell according to the surgeon . On the right the same PCA has labels according to
clusters obtained from the hDPMM. There are 3 hDPMM clusters
We can see that the heterogeneous clusters obtained on the IDENTIREST samples from
hDPMMhave a strong relationship to their corresponding surgeon annotation (Periphery
or Central). We now show that using the genomics data from the IDENTIREST patients,
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we can further validate the hDPMM clustering: We have genomics data available for 178
of the 260 IDENTIREST samples. All these 178 samples fall in two DPMM cluster (i.e.
DPMM cluster I with 151 samples and DPMM cluster II with 27 samples). DPMM cluster
III samples have no corresponding available genomics data. As there is no overlap between
the 50 gene signature used here and the 1072 genes which show copy number changes (see
Chapter 3), we look for enrichment of samples in each hDPMM cluster with certain ge-
nomic characteristics. Qualitatively, it can be seen from Fig.5.8 that the gene expression
pattern from the hDPMM clustering agrees to the corresponding genomic mutations. The
typical GBM aberrations containing samples are defined in Appendix C. Quantitatively,
we find that there is significant enrichment of DPMMCluster I with Non-Typical GBM
samples (p-value of 2:2e  16). The frequency of CNV calls are also significantly different in
DPMMCluster I samples and DPMM cluster II samples. (p-value 7:5e  16). Thus we have
shown that the genomic data (CNV) can be used to validate the clustering obtained from
hDPMMusing transcriptomics data.
Figure 5.8: Results of hDPMM on 178 IDENTIREST samples which also have corresponding genomic data. On the
leđ is the gene expression with the samples being arranged according to the hDPMM. On the right we have the same
sample ordering but the corresponding CNV data being shown. The
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To summarize, we have explored the sample heterogeneity (jointly for Peripheral and
Central Cells) using the modified SBC (hDPMM). The clustering obtained from the hDPMM
model on the transcriptomics data agrees well with the respective genomic changes, thus
strengthening our belief that the clusters that we obtain are indeed biologically distinct.
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“Reading furnishॽ the mind only with materials of
knowledge; it ॾ thinking that makॽ what we read ours.”
John Locke
6
Statistical foundations of the SBC
6.1 Introduction
Survival-based-Bayesian Clustering (as introduced in Chapter 4 and later applied in Chap-
ter 5)is fundamentally an instance of a non-parametric Bayesian model. Bayesian non-
parametric models are becoming increasingly important in Biostatistics, an excellent re-
source in this domain isHHMW10. We first explain the general idea of Bayesian non-parametric
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models.
Probability models usually form the backbone of many statistical problems. Data is seen
as realizations of a collection of random variablesX1;X2; : : :Xn, whereXi itself could be
a vector of random variables corresponding to data that are collected on the i-th experi-
mental unit in a sample of n units from some underlying population. Usually, the working
assumption is that theXis are independently drawn from some underlying probability dis-
tributionG. Bayesian models address the uncertainty that exists aboutG. Let g denote the
probability density function (p.d.f.) ofG. A statistical model arises whenG is known to be
a member gv from a familyG = fgv : v 2 Θg labeled by a set of parameters v from an
index set Θ. Models which are described through a vector v of a finite number of real values
are referred to as finite-dimensional or parametric models. This implies that they can be de-
scribed asG = fgv : v 2 Θ  Rpg: The aim of the analysis is then to use the observed
sample to determine a plausible value for v, or a set which may contain v.
The above assumption which constrains the statistical model to a specific set of parame-
ters may be too restrictive in many situations. Such an assumption on the parametric form
of the distribution may also limit the scope of this type of inference. These problems are
encountered in many areas of statistical modelling in biology where the sample size n is
quite small. Hence, to allow for greater flexibility and robustness against mis-specification
of a parametric statistical model, we need to consider models where the class of densities is
so large that it can no longer be indexed by a finite dimensional parameter v, and we there-
fore require parameters v in an infinite dimensional spaceHHMW10. Inference of such high
dimensional parameter space in an Bayesian setting involves placing priors over the infinite-
dimensional parameter v, such priors are known as Bayesian nonparametric (BNP) priors.
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This is also then taken to be the definition of Bayesian non parametric models. That is, we
define BNP priors as probability models for infinite-dimensional parameters and refer to
the entire inference model as a BNPmodel. The two most popular of BNPs in Statistical
Modelling are: Dirichlet Processes and Gaussian Processes. While Dirichlet Process specify
such a non-parametric prior over probability distributionsTeh11, Gaussian Processes are used
as a prior over an unknown functionsRas04 .
The above described infinite-dimensional parameters of interest can, generally, be viewed
as functions. These functions of interest include probability distributions (such as estimat-
ing the distribution of p(X)whereX is the molecular data from patients), or they could be
conditional trends, e.g. mean regression functions (p(yjX), the probability of observing an
outcome y for a patient, given the molecular dataX). The unique aspect about the SBC is
the fact that it can be viewed as BNP where either i) we are interested to estimate the prob-
ability distribution and hence the clustering property of p(X; y) or ii) we are interested in
estimating p(yjX) as a non-parametric function. This fact is reflected in the ability of SBC
to make two kinds of predictions (both survival predictions as well as class or stratum pre-
dictions). As our current model combines aspects from both explorative clustering models
as well as prediction models, we take a look at SBC from both points of views. It will be
shown in the following sections that SBC can be viewed independently from both these
perspectives. In this regard, we also mention that SBC is a generative approach modelling
thus estimating p(y;X) rather than p(yjX).
The joint modelling (y;X) comes at a cost: As the dimension ofX (molecular data) in-
creases, the SBC concentrates more on fitting a distribution forX rather than p(yjX). In
order for such an approach to be competitive to a discriminatory approach appropriate
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feature selection techniques need to be employed. Thus feature selection is another vital
aspect to SBC which has been explained in detail in last part of this chapter.
6.2 SBC as a clustering model
Our present SBCmodel has similarities to the work of MüllerMEW96 in the area of Bayesian
curve fitting. The same authors provide a R-package ’PPMx’ implementing their idea along
with some later modificationsMQR11. The key idea is to model zi = (yi;Xi) as joint random
variable with a DP prior. Thus the SBCmodel simply reduces to a BNP prior on the joint
distribution of the response and the covariates representable by the following hierarchy:
y1; : : : ynjX;ϕ ind p(yijXi;ϕi)
X1; : : :Xnjγ ind p(Xijγi)
(ϕi; γi); : : : (ϕn; γn)
ind G
G  DP(αG0)
withG0 = G0ϕ  G0γ, this equation leads to the following joint probability model (with
Λ = (γ;ϕ) )
p(y;XjΛ) 
kX
j=1
njp(y;XjΛj ) + α
Z
p(y;XjΛ)dG0(Λ)
The above integral is difficult to calculate because of the complex dependency between γ
and ϕ. The two sets of parameters are locally independent (cluster wise), but globally de-
pendent. This present model was used inMEW96 and then re-branded inMQR11. This tricky
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dependency which has been highlighted inMQ10 forces us to use Auxiliary variable approxi-
mation in our solution (see Chapter 4). While the Bayesian curve clustering works only for
extremely low dimensional data sets with continuous outcome, our SBC approach has been
developed primarily for survival output y and high-dimensional correlated input variable
X. The small sample size along with high-dimensional input also forces the SBC to adopt a
more robust, hierarchical prior over the parameter space Λ = (γ;ϕ)
It is also worth noting that the above model can be cast as what is known as a ’Product
PartitionMixture Model’ (PPM). In such models we model the partition ρn probability
where ρn = (S1; : : : Skn)denote a partition of the n experimental units into kn number of Sj
subsets.
p(ρn) /
nkY
j=1
c(Sj)
where c() is the cohesion function. In a simple DPmodel this is given as c(Sj) = α(jSjj  1).
The SBCmodel can be seen as a modification of the simple DP prior, making the cohesion
function dependent onX, such that p(ρnjX) becomes a function ofX in the following fash-
ion:
p(ρnjX) /
nkY
j=1
g(Xj )c(Sj)
Xj = (Xi)i2Sj . The function g() is a similarity function betweenX points in the same clus-
ter. The form of g() induced by our SBCmodel can be seen inMQR11. A modification to the
above cohesion function was suggested by Park &DunsonPD10. The authors motivate their
method as the modelling task for p(ρnjX) in a different manner than the earlier approach
ofMEW96. These two approaches have been compared with each other along with Hierarchi-
cal Mixture of Experts, FlexMix inMQ10. Their proposed model uses the following modified
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cohesion function:
c(Xj ; Sj ) = α(kj   1)!
Z Y
i2Sj
f2(Xjjv)dG0v(v)
where f2 describes the likelihood model forXi, the base measureG0v is chosen conjugate to
f2 such that the integral can be calculated. Given this, the prior over cluster assignment ρn
can be written:
p(ρn) /
nkY
j=1
c(Xj ; Sj)
PD10 develop a ’Generalized Polya Urn’ Scheme now to update the parameters ϕ (just as
the Polya Urn Scheme which was used to update the joint parameter Λ in the present SBC
method). Hence, this method provides an alternative strategy for updating the parameters
φi of the conditional distribution p(yijXi; φi), avoiding the computation of parameter γi
for the distribution of p(Xijγi), which in many cases may not be that important. We have
described this method as an alternative to the SBC sampling approach so that one can ap-
preciate the subtleties within the SBCmodel along with its different proposed variants in
the literatureMQR11 PD10 . Sampling for the parameter γi for the distribution of p(Xijγi) is
done explicitly in SBC as it also allows us to rank high-dimensional features in γi in terms of
their importance to clustering. This ranking is useful later on when we interpret our SBC
model.
From the above description it’s easy to see that probability models p(ρn) can systemati-
cally be generalized to p(ρnjX) and hence can be termed as covariate-based random parti-
tion models or covariate based product partition model (also known as PPMxmodels in
MüllerMQR11) . The implied conditional distribution p(ρnjX) defines a probability model
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for ρn, indexed by covariatesX, such an approach becomes particularly convenient when
the model is combined with the sampling model for observed data y as (p(yijXi; φi))MQR08.
One important limitation of such a approach, especially in the case of multi-modal data for
X is the specification of a probability model for different types of the co-variates. For a long
list of mixed kind of data formats, it becomes increasingly challenging to define meaning-
ful probability distributions. Such situations are quite common also for many biomedical
applications whereXi could also include patient data like treatment history, age, ethnicity,
insurance coverage,location etc. These details also have to be included in the model without
the explicit assumption of any clustering pattern within it.
6.3 SBC as a predictive model
Another point of view is to look at SBC from a purely predictive perspective. In this con-
text, similarities can be seen with the works of Hannah et al.HBP11 and Shahbaba et al. SN09.
These authors provide a different terminology to their work such as Mixture of Gener-
alized Linear Models or Non Linear Modelling using Dirichlet Process Mixture Model.
Their approach can be summarized as follows: By modelling the joint distribution of the
response variable, y, and of the covariates, x, non-parametrically using Dirichlet process
mixtures, along with keeping the relationship between y and x linear within each compo-
nent of the mixture, the overall relationship between y and x becomes non-linear if the mix-
ture contains more than one component, with different regression coefficientsBIB15. Thus,
the idea of cluster-specific linear relationships that we have in our current SBC approach
provides an elegant approach for modelling of an overall non-linear relationship. In other
words, SBC can be seen as a new class of methods for nonparametric regression. Given a
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data set of input-response pairs, the SBC produces a global non-linear model of the joint
distribution through a mixture of local linear modelsHBP11. The key difference between the
SBC approach and that of Hannah et al. and Shahbaba et al. is the high dimensionality of
xwhich is modelled explicitly using a hierarchical model as well as the nature of the output
being censored survival times in SBC rather than continuous or categorical as used other
works
The predictive model can be understood as a set of the following equations as written
below, where fx represents the assumed distribution ofX (multivariate normal in our case)
and fy is the conditional distribution that yjX follows (truncated univariate normal in the
case of SBC), the form of fy can be varied, thus giving rise to generalized linear models or
even classification models:
P  DP(αG0)
Θ = (Θi;x;Θi;y)jP  P
XijΘi;x  fx(:jΘi;x)
YijΘi;y  fy(:jXi;Θi;y)
The Dirichlet process prior on the distribution P clusters the covariate-response pairs (x; y).
In a predictive setting, the training phase involves observing both x and y. The posterior
distribution of P allows the data to cluster to nearby covariates that exhibit the same kind
of relationship to their response. During the predictive or test phase, when the response is
not observed, predictive expectation E(fy(Yi jXi ) can be understood by clustering the co-
variates based on the training data and then predicting the response according to the model
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associated with the covariates clusterHBP11. Therefore, the DP prior acts as a kernel for the
covariates thereby calculating the distance between two points by the probability that the
hidden parameter Θ is shared.
This kind of modelling provides a useful alternative for predictive models. Many other
powerful predictive models, such as Generalized Linear Models (GLMs) and Gaussian
processes (GP), make assumptions about data dispersion and homoscedasticity. Over-
dispersion occurs when the data variance is positively correlated with the predicted model
mean. The modelling technique described above successfully creates classes of models that
account for over-dispersion. A model is homoscedastic when the response variance is con-
stant across all covariates; a model is heteroscedastic when the response variance changes
with the covariatesHBP11. Models like traditional GLMs or GPs are homoscedastic and hence
give poor data-fits when this assumption is not met. In contrast, the modelling framework
described by SBC captures heteroscedasticity when mixtures of linear models (or GLMs)
are used. The mixture model setting allows variance to be modeled by a separate cluster-
specific parameter or by a collection of clusters in a single covariate location. As a result of
this approach we end up with smoothly transitioning heteroscedastic posterior response
distributions.
Another popular technique that is related to SBC is ’Mixture of Experts’. Mixture of
experts model was the first attempt at using a collection of simple linear models to build a
non linear model and was proposed by Jacobs et al. JJNH91. This model was introduced as a
supervised learning procedure for models that consist of many local experts, each special-
ized for a subset of data. A gating network decides which expert should be used for a given
data point, the parameters of which are learned from the training data. These approaches
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provided fixed number of experts and came with the risk of over-fitting and complicated
model selection. Rasmussen and GhahramaniRG02 extended the number of experts to po-
tentially infinite by defining the gating network to be based on an input-dependent adapta-
tion of Dirichlet process. Later, Meeds and OsinderoMO06 proposed an alternative view of
the Mixture of Experts model by proposing a joint mixture of experts model over covariates
and response variable.
A good way to emphasize the importance of Mixture of Experts Model or generally mix-
ture of predictive models is by looking at the Fig.6.1. The left plot shows data points drawn
from two classes denoted red and blue, in which the background color (which varies from
pure red to pure blue) denotes the true probability of the class label. The center plot shows
the result of fitting a single logistic regression model using maximum likelihood, in which
the background color denotes the corresponding probability of the class label. Because the
color is a near-uniform purple, we see that the model assigns a probability of around 0.5
to each of the classes over most of input space. The right plot shows the result of fitting a
mixture of two logistic regression models, which now gives much higher probability to the
Figure 6.1: Depicধon of mixture of experts models for predicধon. Image reproduced from Christopher Bishop’s book
” Paħern Recogniধon and Machine Learning”Bis06. Explanaধon of the figure is contained in the text
156
correct labels for many of the points in the blue class. Thus identifying the distribution of
pointsX helps us correctly define two different prediction models which then accurately
capture the overall complicated relationship betweenX and y (the class labels).
While discussing SBC as a predictive model, one should also note that it is a generative
model. Generative models generate all possible values of dataX given the target variable y
by concentrating on modelling the generation process of the data, i.e. p(Xjy), this in turn
means that we estimate the joint model p(X; y) as p(X; y) = p(Xjy)p(y). The other class
of predictive models are known as discriminative models which provide a model only for
the target variable p(yjX). Both generative models and discriminative models can be used
for the task of predictions. Generally speaking, generative models have some advantages
over discriminative models such as providing a framework to handle missing or partially
labeled data. They can also, potentially, augment small quantities of expensive labeled data
with large quantities of cheap unlabeled data. Two highly successful examples of predic-
tive models which are generative are: Naive Bayes Classifier and Latent Dirichlet Allocation
(LDA)BNJ03 both of which have been successfully used in applications like document label-
ing and image analysis. These generative models perform well in classifying documents (like
e-mail spam detection) with previously unknown patterns.
At the same time that generative models can be quite successful in many problems, they
can also be computationally intensive. Another critical drawback of generative models
is that finding a good estimate for the joint distribution of (X; y) does not in necessarily
translate into a good estimate of decision boundaries. On the other hand discriminative
models are often preferred for their good class separation abilities and are often computa-
tionally fast. However, using a generative model in our SBC approach allows estimate of
157
the hidden structure in the dataX. This leads to a more interpretable prediction model.
Our SBC approach is based on the intuitive assumption that different regions in the dataX
can have different predictive models and hence modelling p(X; y) allows us to discover the
pattern in the data.
SBC approach also has similarities to curve clustering approaches such as FlexMixGL08
which implements a general framework for fitting discrete mixtures of regression models.
As it is parametric (the number of curves need to specified beforehand) and non-Bayesian it
uses EM algorithm for parameter estimation. It is fairly flexible as regressors and responses
may be multivariate with arbitrary dimension. Our SBCmodel has been compared to
FlexMix; the non-parametric and Bayesian nature of SBCmakes it not only better equipped
for noisy Biological data, it also yields predictive advantage. To overcome limitations of a
parametric mixture of regression models Bayesian profile regression (PR)MPJR10 was pro-
posed. In its original formulation it is closely related to the augmented response model
described beforeMQR11. It’s a non-parametric two-step procedure that flexibly models co-
variatesX (using a DP process prior) that identifies “important” cluster specific covariates
and then then connects them to a data model. This model is an alternative to regression
models, non-parametrically linking a response vector to covariate data through cluster
membershipMPJR10. The initial Profile Regression (PR) model which was motivated from
epidemiological applications considered target variable y as a binary outcome, this was later
extended in PReMiuMLHA+15 which offers many forms of fy(YijXi; : : :) like binary, cate-
gorical, count and continuous responses. PReMiuM also allows to account for the miss-
ing values for the covariates. It has also been discussed in Barcella et al.BIB15 PR (or PRe-
MiuM) can be equivalently represented as a Product PartitionMixture Model. As opposed
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to FlexMix or PR, our SBC approach only uses a survival model, where the target variables
y can be censored, also there is considerably more focus in our SBC approach to robustly
model the high-dimensional inputX.
6.4 Variable Selection
Irrespective of whether we consider SBC as a clustering or a predictive model, it has been
shown that the success such models requires relatively fewer covariates (the dimensionD
of the vectorX). This is necessary because as the number of covariates increase, their in-
fluence on partition probabilities outweighs any information the response y provides for
clusteringQMP15. This often results in a large number of clusters with very few (even single)
observations hence resulting in a poor model fit and out-of-sample prediction as shown
inQMP15. Therefore feature/covariate selection plays an important role in SBC and similar
statistical models. Generally, the covariates are chosen based on their importance in two
different areasBIB15:
1. relevance in determining the clustering of the observationsX, i.e. its effect in distin-
guishing different clusters.
2. effect on the level of a response/target variable through the likelihood of fy(YijXi; : : :)
In our SBCmodel, we adopt two different feature selection (feature importance) strategies
for the above described two tasks. Apart from variable selection another possible technique
to avoid the problem of poor model fit is to decouple clustering of the observationsXi with
the clustering of the response model fy(YijXi; : : :), this was the approach adopted byWade
et al.WDPT14 by proposing a enriched Dirichlet process prior over the two different kinds
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of partition. Again, this scheme was proposed to down weight a covariate’s influence on
clustering. Variable selection is the much more common alternative approach that attempts
to accommodate a large number of covariates. In particular, Quintana et al.QMP15 propose
a variable selection technique based on the PPMxmodel by introducing introducing vj;l
binary indicators for the jth cluster and lth covariate. Covariates can be active vj;l = 1 or
inactive vj;l = 0. The overall prior probability for the partition ρn then can be written as:
p(ρnjX; v) /
nkY
j=1
c(Sj)(
DY
l=1
g(Xvj;lj;l ))
A hierarchical logistic prior is used for p(vj;l). Such a hierarchical prior allows for the shar-
ing of the information about important covariates across clusters. Another approach was
taken by Chung and DunsonCD09 which use Bernoulli variable ηjl (l = 1 : : :D) instead
of vj;l and for clusters j = 1 : : :K) which takes values either 0 (feature omitted) or 1 (fea-
ture selected) for a particular cluster j. Until this point, this approach is identical to that of
QuintanaQMP15, however Chung et al. use a different set of hierarchical priors over η
ηjl  Bernoulli(κj)
To borrow information across mixture components, they use the sparseness-favoring prior
ofCD09:
κj  1(wj = 0)δ0(κj) + 1(wj = 1)Beta(κj; a; b)
wj  Bernoulli(0:5)
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The posterior for ηjl can be then be updated from its conditional distribution. Feature se-
lection again plays an important part in PRMPJR10 and closely resembles the techniques de-
scribed above. The probability that a data point xi is factorized as a product over its features
in the cluster j:
xijηj1; : : : ηjD 
d=DY
d=1
p(xidjηjd)
In the next step, variable selection is then performed by replacing the distribution of each
covariate as followingBIB15:
p(xidjηjd;πd) = πdp(xidjηjd) + (1  πd)rd(xid)
πd 2 (0; 1) is a continuous weight and rd(xid) indicates the proportion of times covariate d
takes value xid. Here. πd indicates that covariate d is informative in terms of clustering. The
authors then define for πd either a Beta hyperprior distribution for each d or alternatively a
mixture of a Beta distribution and Dirac measure. This then borrows information over the
clusters as mentioned above.
The three variable selection techniques describe above allow for the feature selection
of important covariates in clustering of the observation, however they do not address the
question of which covariates are most related to the target variable. This concern was ad-
dressed by Barcella et al.BIBML16 where they introduce a spike and slab penalty to model the
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relationship betweenX and y:
y1; y2; : : : ynjX;Θ; λ ind N(yijxiθti; λ)
xijηj1; : : : ηjD 
d=DY
d=1
p(xidjηjd)
(θi; ηi); : : : (θn; ηn)jG ind G
G  DP(αG0)
where Θ is matrix of parameters with n rows andD columns. Now the base distribution
G0 = G0θ G0η is then given a spike and lab prior as follows:
G0 =
DY
d=1
fπdδ(θd) + (1  πd)N(θdjμd; τd)]Beta(ηdja; b)g
Thus we have given a brief overview of variable selection in statistical models similar to SBC
(broadly termed as covariate dependent Dirichlet Process Mixture Models or DPMMx).
The major objective is to identify the most important covariates for the partition of the
observations. From a statistical point of view variable selection in DPMMx like models is
particularly necessary as higher dimensional covariates can dominate the DPMMx likeli-
hood. Solutions proposed in the literature often involve introduction of latent variables
which mitigate the effect of specific covariates in determining the partition . In other ap-
plications it may also be important to identify those covariates that best explain a response
variableBIB15. The variable selection introduced in Barcella et al.BIBML16 applies variable se-
lection in regression settings by specifying spike and slab distributions as base measures.
In our SBC approach we use another popular method for Bayesian variable selection, viz.,
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Bayesian LASSOPC08.
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7
Conclusions
7.1 Overview
The present work is an attempt to better understand disease heterogeneity in patients (and
tissue samples) by leveraging the large amounts of molecular data that is presently being
made available from large patient cohorts. In the context of cancer, this large amounts
of molecular data has not only provided new insights into the biological diversity of hu-
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man cancers SML15 but also enabled the possibilities to discover previously unknown disease
subtypes. A better understanding of heterogeneity within the disease can then be made
use of to deliver better personalized medicine solutions. Therefore, our work is useful in
identifying/classifying patient strata based on certain discriminating molecular features
between patient sub-groups, in other words defining sub-groups based on sub-group spe-
cific biomarkers can be understood from the perspective of refining molecular disease tax-
onomies. Such taxonomies can potentially play a role in two important ways:
• Development of targeted therapies against certain patient sub-groups. An example
of such an approach in GBM is the use of targeted cancer immunotherapy for block-
ing the PD-1/PD-L1 pathwayXHIY17. The success of such a targeted approach relies
heavily on the ability to understand the right patient strata which need to be treated
with immunotherapy.
• Better understanding of clinical therapy response vs. non-response. Typically, GBM
(or other cancers) is treated with chemotherapy after surgery, but a considerable frac-
tion of patients is chemotherapy resistant. Looking into therapy resistance from the
perspective of molecular strata, which are also clinically supported, might be a way to
understand and potentially overcome therapy resistance in the future.
From a clinical point of view, the work in this thesis can also be thought of as a supplemen-
tary decision support system. For example, in the concrete case of our RIvsRU study, such
a classifier could be useful for clinicians to decide targeted radio therapy for patients. In
clinical practice, such a classifier can be translated into a prognostic toolkit (a customized
gene assay) which can be used in a cost-effective manner. This prognostic toolkit will only
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need the gene expression of a handful of genes which are biomarkers for progression. Such
a prognostic toolkit, however, would first require a prospective validation for the RIvsRU
classifier. Furthermore, the prognostic toolkit would be subject to clinical trials for regula-
tory approval.
7.2 Achievements summary
The thesis introduces the concept of patient stratification, personalized medicine and the
use of modern high-throughput data in the introductory chapter. This is further motivated
by giving a case study example of Glioblastoma. Glioblastoma has been used throughout
the thesis as one of the primary disease test cases. This is in part because of the IDEN-
TIREST project which aimed at studying the recurrence of Glioblastoma and devising new
therapeutic approaches.
Next, the thesis provides a brief introduction to the vast field of -omics data and its use in
personalized medicine. The use of -omics data in statistical modelling comes with a whole
range of issues, most notably that of high dimensionality and correlation. This is touched
upon in Chapter 2 along with standard paradigms for machine learning methods for pa-
tient stratification. The goal in this chapter was to motivate the need to look at multi-omics
data sets in the context of patient stratification. A detailed qualitative review for many such
statistical and machine learning techniques is then provided which highlights the challenges
and strategies in multi-omics data integration for patient stratification.
Next, the use of actual statistical methods on Glioblastoma patients is explored in the
context of the IDENTIREST project in Chapter 3. After the initial project description
along with the Pilot Study, the focus was on the key question of exploring heterogeneity in
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the samples using multi-omics data (mRNA and CNV). We were able to see differences be-
tween the Central and Peripheral samples on both kinds of omics data (mRNA and CNV).
We found consistent patterns between mRNA and CNV data for some of the genes which
showed strong differential expression between Peripheral and Central Samples.
Following on that, we were also able to show the differences between the Central and Pe-
ripheral samples using previously established classification scheme of Verhaak et al.VHP+10b.
As a final application of Machine Learning based classifiers we showed that using transcrip-
tomics data we were able to successfully predict the site for tumor recurrence. We show
the good predictive performance first via cross-validation scheme and then on an indepen-
dent validation set. We next provided biological interpretation and visualization of our four
pathway signature. Notably, our signature also contained strong survival information (PFS
and OS), thus adding another layer of interpretation.
This RIvsRU classifier is envisioned as a decision support system for the clinicians. The
vision is to enable preventive radio-therapy, which is targeted against the location of most
likely tumor recurrence. To enable this vision there are several steps needed:
• A prospective clinical validation of the RIvsRU classifier, which demonstrates com-
parable prediction performance to what we observed so far. Currently, we estimate
that around 100 patients are needed for this purpose.
• After the prospective validation a clinical study would then need to show the efficacy
of such a targeted radio therapy on the recurrence of GBM in patients when com-
pared to standard of care.
• If indeed the benefits of targeted radio therapy can be demonstrated, the classifier
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would then be needed to be translated into clinical practice using a cost-effective cus-
tomized assay. In this case, the model parameters have to be translated from the cur-
rent gene expression assay platform to the much smaller, customized assay platform.
The final goal there would be the development of such a customized assay as a prog-
nostic toolkit, which can be used in day-to-day clinical practice.
• As with any other diagnostic/prognostic tools, there needs to be rigorous clinical
trials approved by the regulatory agencies (FDA,EMA) before it can be brought into
the market.
• Finally, such a prognostic tool would also need a Cost-benefit analysis taking into
account the potential benefit on the health of patients in relation to the overall costs
for developing such a prognostic tool.
Hence, we can understand the clinical potential of our RIvsRU classifier and the future
steps that need to be taken in order to translate it into a clinically useful prognostic tool.
The Survival Based Bayesian ClusteringAF17 is introduced in Chapter 4. This technique
is a fully Bayesian clustering algorithm which takes in clinical end-points of patients along
with heterogeneous -omics data and accomplishes two key tasks in one:
• clinically relevant patient sub-group identification on training data and
• prediction of patient subgroup and survival time on testing data.
Our SBC algorithm was motivated by the need to approach the problem of patient stratifi-
cation taking into account patient specific survival risk models. Effectively, we get clinically
and biologically relevant patient subgroups out of our approach. Another important moti-
vation was the predictive utility of our method that we demonstrated using cross-validation
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results on two important cancer data sets. We also compared the SBCmethod to ad-hoc
techniques and found that SBC outperformed the competing methods. The key ability of
SBC to identify patient-subgroups differing in survival constitutes an advantage compared
to existing approaches. Furthermore, SBC is also principally able to take into account more
than one -omics data source (mRNA and miRNA). Moreover, we also demonstrate that
certain sub-types from our model are particularly enriched in certain biological markers
(for example ER status for breast cancer) and also correlate strongly with some sub-types
in the well established classification schemes. This coupled with the ability of SBC to iden-
tify sub-group specific biomarkers which have also been reported in the literature makes
SBC a potent novel tool in the area of patient stratification and a vital step towards a more
clinically relevant dissection of patient heterogeneityAF17.
As a follow up on the practical applications of SBC, we demonstrate its utility in the
context of the IDENTIREST project in Chapter 5. We explore the validation of the SBC
model trained on Verhaak data set to our IDENTIREST cohort. We were able to predict
potentially clinically relevant patient strata (with respect to Overall survival). We were also
successful in finding distinct genomic patterns (CNV) in the predicted patient strata which
serves yet again to validate our prediction results. As a second application, we use a vari-
ation of SBC (hDPMM) to better understand the heterogeneity of the samples (and pa-
tients) in an unbiased manner. We used the hDPMM to analyse the full cohort of IDEN-
TIREST samples. The clustering that we obtained from fitting the hDPMMwas enriched
in the surgeon defined classes (Peripheral and Central). Also using the genomics data (us-
ing CNVs) we further tried to validate the hDPMM clusters. Thus in both the sections of
this Chapter we have used multi-omics data sets (gene expression and CNV data) from the
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IDENTIREST cohort to validate our results.
We conclude the thesis with an elaborate statistical description of our SBCmethod in
Chapter 6. We first motivate SBC as a general generative Bayesian non-parametric model.
We next explain two fundamentally distinct ways to look at SBC- a) from a non-parametric
clustering point of view and b) from a non-parametric predictive modelling view. In this
context, we contrast SBC with other popular machine learning techniques like Mixture of
Experts and Bayesian Profile Regression. Similarities between Generalized Linear Models
and SBC are also discussed. In the end, we also provide a brief overview of variable selection
in models similar to SBC. These theoretical perspectives on the SBC also point to the statis-
tical shortcomings and possible workarounds for such shortcomings. Overall, this chapter
gives an insight to the statistically involved nature of our proposed SBC approach and di-
rections for future methodological improvements in the same.
Our SBCmethod can be judged to be of value from both statistics/ machine learning
perspective as well as clinical/medical perspective. The methodological statistical develop-
ments are driven from the needs of clinical applicability and we show that the results ob-
tained can be interpreted from a biological point of view. As such the SBC can be seen as
an important tool which can help/augment clinical decision making. In a wider context, we
believe that this thesis is a step closer towards the goal of achieving personalized medicine
solutions using molecular -omics and clinical patient data. This thesis fills an important
void in the scientific literature on the need to explore patient heterogeneity using multi
-omics data in combination of clinical data. We have also shown that the application of
machine learning techniques on such data can indeed be a crucial part of the puzzle in the
field of patient stratification. Therefore, this work is of value for health care data scientists,
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biologists studying disease mechanisms and medical doctors treating patients.
7.3 Future directions
Looking ahead in the future, this thesis can be a good starting point for further explo-
rations of the fusion and interplay of clinical and molecular data for the development of
predictive machine learning patient stratification algorithms. There are broadly two differ-
ent directions one could take: a) looking into various novel sources of molecular/clinical
data apart from ones used in this thesis (e.g. bioimaging data, electronic health records,
wearable mobile technologies etc.) and b) looking into different algorithms for patient
stratification (e.g. deep learning approaches, matrix factorization or graph-based approaches).
The stratification algorithms then need to translated into clinical practice by testing them
in clinical studies. Success in clinical studies of these stratification techniques will be the
ultimate criterion for their wide-scale applicability, acceptability and adoption.
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B
Sampling Algorithm for SBC
The appendix explicitly lists the individual steps for the Gibb’s sampling used for model
fitting SBC. We have defined the prior distribution of the parameters in Chapter 4. The
goal of fitting a hierarchical Bayesian model (like SBC) is to obtain the joint distribution
of all the parameters and hyper parameters in the model. Gibb’s sampling is used when
the overall joint distribution of the parameters is difficult to obtain, however based on the
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hierarchical structure, conditional distributions of each of the variables can be obtained
(conditioned on the variables in the Markov blanket of that variable). The Hierarchical
structure of the SBC (as shown in figure 4.1) provides a Bayesian Network representation of
our parameters and is used to define the conditional distribution for each individual param-
eter (represented as one node). It can be shown that iteratively drawing samples from the
conditional distribution for each parameter constitutes a Markov Chain and the stationary
distribution of that Markov chain is the joint distributionGCSR04.
Now we describe in detail the overall sampling scheme. Here are some notations: Let
Θk = fμk; Skg be the parameters of the hierarchical GaussianMixture model (GMM),
Bk = fβ0k; βk; σ2kg be the parameters of the AFT bayesian LASSO (BLASSO) model.
Correspondingly, we have hyper-parameters of the hierarchical GMMH1 = fξ; ρ;W; φg,
and of the AFT BLASSOH2 = fλ; τ2g. If we have k = 1 : : :K  occupied clusters at any
moment, each containing nk data points, the total number of parameters are Φk = fΘk;Bkgk=1:::K 
andH = fH1;H2; αg hyper-parameters apart from cluster-indicator variables c1; c2; : : : cN.
The gaol is to sample each of these variables by following at iterative strategy which can be
summarized as follows:
• Update all parameters Φk1:::K
• Update all the hyper-parametersH
• Update all the cluster indicator variables c1; c2; : : : cN
• Update DP concentration parameter α
As described in Chapter 4, letG0(α;H) be the overall prior distribution over the parameter
space fΦg. While updating the cluster-indicator variable, we follow the Algorithm 8, as
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described in NealNea00 with the Auxiliary variables set to twoU = 2:
Algorithm 1 SBC Gibb’s Algorithm
1: procedure Update Cluster Indicator ci(U =2)
2: For each i = 1 : : :N
3: Let k  be the distinct number of active clusters
4: Check if the present cluster assignment also has other data points:
5: if ci = cj for some j 6= i then
6: Draw Φk +1 and Φk +2 independently fromG0(α;H)
7: end if
8: Check if the present cluster assignment was the singleton data point:
9: if ci 6= cj for all j 2 1 : : :N then ci = k  + 1,
10: Assign Φk +1 = Φci
11: And Draw Φk +2 fromG0(α;H)
12: end if
13: Sample ci from the following distribution
14: if k = 1; 2 : : : k  then
15:
p(ci = k) / n i;kN  1+ αN (wijΒk)N (XijΘk)
16: end if
17: if k = k  + 1 or k = k  + 2 then
18:
p(ci = k) / αN  1+ αN (wijΒk)N (XijΘk)
19: end if
20: i i+ 1.
21: goto top.
22: end procedure
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GBM specific mutations
Here is a list the typical genomic mutations in GBM
• Gains on Chromosome 7
• Losses on Chromosome 1p, 6q, 9p, 10q and 13q
• Loss of Heterozygosity on Chromosome 10, 14q, 17p13.3
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